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Abstract 
This thesis involved the development of two Biosensors and their associated assays for 
the detection of diseases, namely IBR and BVD for veterinary use and C1q protein as a 
biomarker to pancreatic cancer for medical application, using Surface Plasmon 
Resonance (SPR) and nanoplasmonics. SPR techniques have been used by a number of 
groups, both in research [1-3] and commercially [4, 5] , as a  diagnostic tool for the 
detection of various biomolecules, especially antibodies [6-8]. The biosensor market is 
an ever expanding field, with new technology and new companies rapidly emerging on 
the market, for both human [8] and veterinary applications [9, 10]. 
In Chapter 2, we discuss the development of a simultaneous IBR and BVD virus assay 
for the detection of antibodies in bovine serum on an SPR-2 platform. 
Pancreatic cancer is the most lethal cancer by organ site, partially due to the lack of a 
reliable molecular signature for diagnostic testing. C1q protein has been recently 
proposed as a biomarker within a panel for the detection of pancreatic cancer. The third 
chapter discusses the fabrication, assays and characterisation of nanoplasmonic arrays. 
We will talk about developing C1q scFv antibody assays, clone screening of the 
antibodies and subsequently moving the assays onto the nanoplasmonic array platform 
for static assays, as well as a custom hybrid benchtop system as a diagnostic method for 
the detection of pancreatic cancer. Finally, in chapter 4, we move on to Guided Mode 
Resonance (GMR) sensors, as a low-cost option for potential use in Point-of Care 
diagnostics. C1q and BVD assays used in the prior formats are transferred to this 
platform, to ascertain its usability as a cost effective, reliable sensor for diagnostic 
testing. We discuss the fabrication, characterisation and assay development, as well as 
their use in the benchtop hybrid system. 
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1.1 Introduction to Biosensors and Point-of-Care Diagnostics 
Scientists have traditionally developed technologies in response to the needs of the 
developed world's medical community. As a result, the diagnostic systems on which 
they have been implemented have met the requirements of well-funded laboratories in 
highly regulated and quality-assessed environments [11]. However, such approaches do 
not fit all of the needs of the medical community, as they are high cost, can take days or 
weeks to produce results and require highly trained personnel. Nowadays, front line 
medicine requires more rapid diagnosis for trauma and ICU patients to diagnose 
medical conditions that require rapid intervention to improve patient prognosis [12]. 
Cancer patients can improve their chances of survival greatly by diagnosing their 
condition in the curable stages of the disease [13]. populations in underdeveloped 
countries that are affected by illness or are afflicted with infectious diseases have, at 
best, access to poorly resourced health care facilities with almost no supporting clinical 
laboratory infrastructure [14]. Globalisation also means that third world infectious 
diseases can travel easily outside their borders and therefore also concern the developed 
world. For example, the Ebola virus epidemic in West Africa in 2013 overwhelmed the 
healthcare systems of Liberia, Sierra Leone and their neighbouring countries. Currently, 
it is difficult to identify Ebola because its symptoms, such as fever, are generic and also 
seen in commonly occurring diseases such as malaria and typhoid fever. Existing 
laboratory techniques are based on reverse transcription polymerase chain reaction (RT-
PCR) and quantitative PCR; however, they are not portable and affordable in the 
developing world [14].                                   
Point-of care (POC) biosensors are a diagnostic platform aimed to address these issues. 
It is meant to be performed at or near the site where clinical care is delivered, outside of 
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the well-controlled environment of the traditional laboratory. They must have the same 
confidence of result, to evaluate the disease status of a subject on site in order to 
implement timely necessary intervention. Although the main application of rapid tests is 
in the field of medical diagnostics, such assays are also necessary for veterinary testing, 
environmental monitoring and food quality testing [15]. Point of care diagnostics would 
allow farmers to rapidly establish a disease outbreak before affecting the entire herd and 
potentially resulting in an epidemic, thereby limiting economic damage. Environmental 
testing can evaluate drinking water in developing countries for water-borne diseases like 
cholera. Food quality testing can determine food-borne pathogens, such as E.Coli and 
Salmonella on site [16]. 
Current Point of Care Tests 
The two dominant POC systems on the markets are Dipstick and lateral-flow, see 
Figure 1.1. [16]. These are the two universal assay formats, as they are lightweight and 
compact, and provide qualitative results without external instrumentation.  
 
 
Figure 1.1 a) A typical lateral flow device for point of care diagnostics. b) Shows a 
schematic for a typical dipstick test. 
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The basic principle of both technologies is based on a series of capillary beds, such as 
pieces of porous paper or sintered polymer, which enables the migration of sample 
fluids that are soaked up at the sample pad to the conjugate pad, where a ligand that is 
immobilised on the surface may react with a target molecule, if present. Turnover time 
is often a matter of minutes; however, the short assay time for these formats can result 
in a decrease of sensitivity. Also, existing formats have limitations in the quantification 
of analyte concentrations. Hence, the demand for sample preparation, improved 
sensitivity and user-interface has challenged the commercial products [13, 17]. Also, 
recent research developments in diagnostic assays have increased capabilities; sensors 
and readout devices were expanded to accommodate multiplex assay platforms, which 
might transcend the capabilities of the existing design format of diagnostic tests [17]. 
Biosensor Formats 
The methods employed for biosensing are generally piezoelectrical, electrochemical or 
optical. Although, electrochemical and piezoelectrical methods work well for certain 
applications, optical detection is generally regarded as superior and is the method most 
widely employed in laboratory clinical diagnostics [13, 18]. Unlike the other two 
formats, optical detection using surface plasmon resonance (SPR) has the advantage of 
giving real-time, quantifiable data that lends itself to the kinetic analysis of the 
biomolecular interaction [19, 20]. The most recent academic and commercial 
developments in SPR diagnostic systems combines the optical system with 
microfluidics sample addressing, and is extensively used in benchtop diagnostics [2].  
However, despite a growing focus from the academic community, and wide application 
in benchtop diagnostics, optical microfluidics has yet to produce many commercial 
devices for point-of-care (POC) biosensors. One of the main reasons for this is the 
difficulty in producing low-cost, sensitive, and portable optical detection system. 
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Conventional optical systems are costly, require careful alignment, and do not translate 
well to POC devices. Conventional SPR sensing also requires a prism or grating coupler 
to excite propagating plasmons on the metal surface, making it therefore quite a 
complex system to miniaturise, as well as being costly. The sensitivity of the system 
may also make it prone to background interferences, for instance from non-specific 
binding of non-target molecules. Furthermore, many optical detection paradigms, such 
as absorbance and fluorescence suffer at smaller geometries because the optical path 
length through the sample is shortened. POC Fluorescent immunoassays also require 
more complex read-out equipment for excitation and detection. In this work, we 
describe the investigation of label-free, multiplexed sensing on benchtop instruments 
towards point of care application [2, 21, 22].  
1.2 The Immune System 
The immune system is a complex biochemical system that protects a body against 
disease [23]. In higher animals, including humans, it is divided into two main 
components; the innate immune system, which one is born with, and the adaptive or 
acquired immune system, which develops in direct response when challenged by 
specific foreign threats [23, 24]. The innate immune cells are the first response line of 
defence; its role includes antigen presentation, activation of complement, and 
recruitment of specialised immune cells to the site of infection [25]. The cells of the 
adaptive immune system are known as lymphocytes, of which there are two types; T-
Cells, which are involved in cell mediated immune response; and B- cells, which 
generate antibodies that are specialised to recognise a specific antigenic site on a target 
molecule [26]. 
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1.2.1 Antibodies 
As mentioned in section 1.1, B-cells produce antigen specific immune cells called 
antibodies during the state of infection by a foreign pathogen. Antibodies belong to a 
group of proteins called immunoglobulins (Ig) that are present in the blood of 
immunised animals [25]. Immunoglobulins are mostly found in plasma or serum and 
comprise of five major classes, listed in order of abundance: IgG (immunoglobulin G), 
IgA, IgM, IgD and IgE [25, 27, 28]. Each is composed of four polypeptide chains, two 
identical heavy chains (H) and two identical light chains (L) that form a “Y” shaped 
molecule (see Figure 1.2). The H chains differ in antigenic and structural properties 
between the immunoglobulins, and determine the class and subclass of the antibody. 
The two L chains are either of type kappa, κ; or lambda, λ. The distribution of κ and λ 
chains differs between the classes and subclasses of Immunoglobulins, as well as 
between different species [28]. Covalent interchain disulphide bridges within the 
antibody structure join L to H and H to H chains. They impart a greater stability to the 
antibody molecule by participating in the tertiary structure. The upmost domains on the 
antibody heavy and light chain variable regions that are in direct contact with the 
corresponding target site of the antigen are termed Hypervariable regions [25, 29]. 
Somatic hypermutation within antibody producing B-cells allow diverse antigenic 
specificities to be recognized and allow for the antibody specificity towards its target 
antigen [25, 29]. 
 IgG is by far the most utilised antibody in antibody diagnostic techniques, due to its 
role in secondary immune response [29]. 
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Figure 1.2: Structure of an antibody molecule. The constant region (Fc) is linked to the 
Variable region (Fab’) via disulphide bonds that link the molecule together at the hinge 
regions. The variable region contains the antigen binding site or paratrope, which is 
specific to a particular target site (epitope) on an antigen. 
 
1.2.2 IgG 
IgG has a molecular weight (MW) of 150 kDa. The two H chains of the IgG molecule 
are of type gamma (γ), whereas the two light chains are designated either κ or type λ, 
which gives IgG  the general formula of γ2 κ2 or γ2 λ2. That denotes that one molecule 
of IgG is composed of two γ H chains, and two L chains of either type κ or type λ [30-
32]. IgG (as well as any of the other classes of antibody), can be structurally broken 
down by proteolytic digestion (using enzymes) and reductive dissociation [32]. 
Digestion by papain results in two monovalent antigen-binding fragments (Fab) and one 
crystalline fragment (Fc), by cleaving the bond between the interchain disulphide 
bridges [31, 32]. The enzyme Pepsin results in one bivalent antigen-binding fragment, 
F(ab’)2, by cleaving the disulphide linkers below the hinges of the molecule. In this 
case, the Fc fragment is destroyed. Reductive dissociation of the antibody molecule 
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splits the interchain disulphide bridges, resulting in two heavy chains and two light 
chains [32, 33]. 
1.2.3 Polyclonal Antibodies 
Polyclonal antibodies are antibodies of the same species, directed against various 
epitopes (target sites) of the same antigen [34]. They are generated by different B-cell 
clones of the host and as a consequence are immunochemically different, although they 
are produced in response to the same foreign threat [25]. Polyclonal antibodies can have 
slight variance in specificities and affinities. Polyclonal antibodies are most frequently 
grown in rabbits but also produced in other mammals including goat and cow [34].  
1.2.4 Monoclonal Antibodies 
Unlike Polyclonal antibodies, Monoclonal antibodies are a population of the same 
species of immunoglobulin, generated against the same epitope of an antigen [35]. The 
antibodies are produced by a single B-cell clone and are therefore immunochemically 
the same. Monoclonal antibodies are most commonly from murine origin [36]. 
1.2.5 Antibody Affinity 
The Antibody-Antigen binding events are non-covalent and reversible; They are formed 
by a combination of electrostatic interactions, van der Waals forces and hydrogen bonds 
[37, 38]. Affinity measures the strength of the bond between the epitope of the antigen 
and the paratrope (corresponding binding site) of the antibody molecule. It follows the 
basic law of thermodynamic principles that defines any reversible biomolecular 
interaction:  
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Where KA = affinity constant  [Ab] = molar concentration of unoccupied binding sites 
on the antibody [Ag] = molar concentration of unoccupied binding sites on the antigen 
[Ab-Ag] = molar concentration of the antibody-antigen complex.  
Basically, KA conveys the amount of antibody-antigen complex at equilibrium [37]. 
High affinity antibodies will bind a greater amount of antigen in a shorter period of time 
than low-affinity antibodies. The affinity constant can therefore vary  for antibodies 
from anything below 105 mol-1 to above 1012 mol-1, and can be influenced by certain 
factors, including temperature, pH  and type of buffer [38, 39].  Monoclonal antibody 
affinity can be determined accurately, because they are a homogeneous population and 
selective for a single epitope on the antigen, whereas Polyclonal antibodies are a 
heterogeneous mix of different affinities against several epitopes, so only an average 
affinity can be deduced [39, 40].  
The accumulated force of the multiple affinities between the antibody-antigen complex 
is termed avidity [40]. 
1.2.6 ScFv and Antibody Application 
The specificity of antibodies to their target antigen makes them one of the most 
powerful tools in medical diagnostics and therapy [41]. They are currently one of the 
fastest growing classes of therapeutic molecules. Single chain variable fragments (scVf) 
are recombinant antibodies,  that are becoming increasingly popular in medical 
application, due to their more economical production, when compared to a full length 
antibody [42, 43]. They are smaller and lend themselves more readily to genetic 
manipulation. A scFv fragment has an approximate molecular weight of 30 kDa, and 
consists of the variable heavy (VH) and variable light (VL) chains of the functional 
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antigen binding domain of an antibody, which are joined together by a flexible peptide 
linker [42, 44] (see Figure 1.3). The advantages of using scFv over full length antibody 
molecules in diagnostics include a greater coverage of the sensor surface with available 
binding sites, due to the smaller size of the molecule; and directionality, as the molecule 
by definition only consists of the antibody binding sites, unlike full antibody molecules, 
which may point up at the Fc region, preventing binding to the antigen [44, 45]. They 
are also more cost effective to produce, as they can be grown in genetically modified lab 
strain bacteria, whereas full antibodies require to be grown in mammalian cell lines or 
in a host animal, due to the need for glycolisation of the molecule [45-47]. 
 
Figure 1.3: Full antibody molecule and fragments. The fragments origin from the 
variable region of the antibody, and are joined by a linker to make a scFv [48]. 
 
1.2.7 The Complement System and C1q Protein 
The human complement system is part of the innate immune system, designed to handle 
bacterial as well as viral infections, especially to block their invasion into the 
bloodstream. It is also a key participant in the immune and inflammatory response at 
sites of tissue injury and debris deposition and instructs the adaptive immune response 
[49, 50]. The human complement consists of more than 20 proteins present in plasma 
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and on cell surfaces that interact with each other to produce biologically active 
inflammatory mediators that promote cell and tissue injury [51, 52]. There are three 
biochemical pathways that activate the complement system: the classical complement 
pathway, the alternative complement pathway, and the lectin pathway [51]. C1/C1q 
protein complex is the initiator of the complement cascade in the classical pathway. 
Activation occurs when C1 protein binds with its C1q subunits to the Fc fragments of 
IgG or IgM antibodies in response to the formation of antibody/antigen complexes [52, 
53]. C1q is a 410 kDa protein formed from 18 peptide chains in three subunits of six. 
Each six peptide subunit consists of a Y-shaped pair of triple peptide helices joined at 
the stem and ending in a globular non-helical head, see Figure 1.4 [54]. 
 
 
Figure 1.4: Structure of C1q protein. 
C1q has two main structural components; the globular head and the collagen-like 
fibrous portion. The globular head binds to antibody/antigen complexes, damaged 
neurons, biological debris and foreign pathogens. The collagen-like fibrous portion 
binds to receptors to initiate phagocytosis, and classical pathway activation [54, 55]. 
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C1q deficiency in humans has been identified as a cause for a number of autoimmune 
disorders, including systemic lupus erythematosus and rheumatoid arthritis [56]. Recent 
research in cancer diagnostics has also identified elevated C1q protein levels as a 
biomarker in the occurrence of a number of cancers, notably lung cancer and pancreatic 
cancer, which makes C1q a valuable candidate as biomarker on a panel to diagnose 
those high mortality cancers.  [57, 58].  
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1.3 Pancreatic Cancer 
Early detection of cancer has improved survival for several types of the disease, 
including breast, colon, prostate, and cervical cancers [59-61]. Unfortunately, for 
pancreatic ductal adenocarcinoma (PDAC), effective early detection and screening are 
currently not available and tumours are typically diagnosed at a late stage, frequently 
after metastasis [58]. PDAC is generally considered to be incurable by available 
treatment modalities, with a 5-year survival rate of less than 4%. PDAC is the most 
lethal of all cancers by anatomic site.  Existing biomarkers for this disease are 
inadequate [58, 62]. The most utilised biomarker to date, CA19-9, has been employed 
as an early detection marker in pancreatic cancer, however, the sensitivity and 
specificity of this biomarker are low, and serum levels are also significantly increased in 
inflammatory diseases of the pancreas and biliary tract [63, 64]. Therefore, CA19-9 is 
not useful for early diagnosis, mass screening, distinguishing between PDAC and 
chronic pancreatitis, or the targeting of therapeutics. In the absence of good biomarkers, 
80% to 90% of PDAC cases are diagnosed too late in the disease process for surgical 
intervention to be an effective option [58, 65]. Among the few cases of PDAC patients 
for which surgical intervention is an option, most patients ultimately die of recurrent or 
metastatic disease. Resistance to chemotherapy and radiation, whether intrinsic or 
acquired, is a major cause of treatment failure in PDAC. Specific chemotherapeutic 
agents, such as gemcitabine, are able to induce significant sensitisation of the cancer 
cells to radiation [66-68]. This has made gemcitabine combined with radiation the best 
nonsurgical therapy for PDAC. However, few patients with PDAC benefit from the 
chemosensitising effects of gemcitabine, and no way currently exist to predict which 
patients will benefit from combined treatment [69]. Despite major efforts, no single 
biomarker has been currently identified as a molecular fingerprint for PDAC. However, 
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recent research developments have pinpointed a panel of biomarkers that show 
promising results as a PDAC serum biomarker signature [64, 70]. C1q protein is one of 
the biomarkers of this panel, showing elevation in serum even in early stages of the 
disease, which in conjunction with other biomarkers on the panel, may allow for early 
detection of PDAC and therefore greatly increase the prognosis for survival of the 
patient [70]. 
1.4 BVD Virus 
1.4.1 BVD Virus Taxonomy and Morphology and Genotype 
The BVD virus belongs to the family of Flaviviridae. It was first isolated in 1946 by 
scientist at Cornell University, after an outbreak of an unknown cattle disease 
previously, in Saskatchewan, western Canada  [71]. Affected cattle typically suffer from 
watery, sometimes bloody, diarrhoea, fever, and mucous membrane erosions, as the 
most common symptoms. The name "Flavivirus" is derived from the Yellow Fever 
virus (flavus = lat. yellow). The Flavivirus family consists of the Flavivirus, Pestivirus 
and Hepacivirus genera [72, 73]. BVD virus, as well as Classical Swine Fever virus and 
Ovine Border Disease virus, are part of the Pestivirus genus. Apart from yellow fever, it 
is also related to viruses such as the Japanese Encephalitis virus and West Nile virus, 
which belong to the genus Flavivirus, and Hepatitis C, which belongs to the genus 
Hepacivirus [72-74]. BVD virus has a diameter of 50 - 70 nm, and is therefore among 
the smaller viruses. Figure 1.5 shows the structure of the virus; It has an icosahedral 
capsid structure (consisting of one single capsid protein) and is enclosed by an envelope 
(3 virus coded membrane proteins) [75, 76].  
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Figure 1.5: Structure of BVD Virus 
BVD comprises of a group of viruses, which differ in their nucleotide sequence, 
antigenic qualities and in their effect on the host cells. There are two genotypes 
(BVDV-1 and BVDV-2) and two biotypes; cytopathic, which damages the cells, and 
non-cytopathic, which does not [77, 78] . BVDV-1 and BVDV-2 have several features 
in common. Both BVDV-1 and BVDV-2 can trigger serious disease; the majority (70 -
90 %) of the infections, however, are asymptomatic, which indicates that differences in 
genetic structure do not account for virulence [78, 79]. Both genotypes also occur as 
cytopathic and non-cytopathic biotypes [79]. Non-cytopathic infections of both 
genotypes of virus can cause chronic, persistent infections. Cytopathic biotypes are the 
causative agent of mucosal disease [80]. 
BVDV-1 occurs more frequently than BVDV-2, it is the “classic” strain of the virus, 
whereas BVDV-2 appears to be a more recent mutation. It was first isolated in the 
1980’s [80-82]. 
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Intrauterine Infection 
If a previously uninfected cow is confronted with BVD disease during pregnancy, its 
foetus may become infected in utero. This event has different consequences, depending 
on the timing of infection [83]. In the first month of gestation, there is the possibility of 
re-sorption of the embryo, which could result in reduced fertility of the dam. Between 
two to four months of gestation, infection with a cytopathic biotype causes abortion, 
whereas infection with a non-cytopathic virus strain results in persistent infection of the 
foetus (PI animal) [83-85]. In the majority of cases, such calves are born without 
apparent physiological defects, but may contract Mucosal Disease and are carriers for 
BVDV [83]. Infections at about five months into gestation result in birth defects. The 
foetuses infected during that period are either aborted, weak, or are stillborn. Foetuses 
infected after that period develop antibodies, due to the maturation of the immune 
system. These calves are born physiologically normal, and are immune (see Figure 1.6) 
[84, 85]. 
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Figure 1.6: Effect of BVDV infection at different gestational periods in cattle. Infection 
in the first month results in abortion or re-absorption of the embryo. Between two and 
four months, infection with the cytopathic type of BVD causes abortion of the foetus, 
whereas infection with a non-cytopathic strain results in a persistently infected animal; 
infection at about the five month mark may result in birth defects. Foetuses infected 
after that period develop antibodies, and are born immune. 
1.4.2 PI Animals  
As mentioned above, intrauterine infections with non-cytopathic BVD virus between 
the second and fourth month of gestation result in persistently infected animals (PI 
animals). These PI animals play a key role in the epidemiology of BVD disease [86]. 
They constantly shed virus in secretions (i.e. saliva, urine, semen, etc) and faecal matter 
in high concentrations. They do not produce antibodies against the virus, as the immune 
system does not recognise the virus as a foreign pathogen, due to the infection occurring 
before the full maturation of the immune system in utero [86]. For most part, PI-animals 
are clinically inconspicuous, as they appear physiologically normal and are serum 
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antibody negative. Some PI animals are poor doers and susceptible to secondary 
disease. They can be identified more easily and can be removed immediately from the 
herd. [87, 88]. 
All PI animals are at risk to suffer from Mucosal Disease, which occurs exclusively in 
persistently infected animals [88, 89]. This disease relates to the immunotolerance of 
the PI animal to the BVD virus [77]. The host immune system fails to recognise the 
virus as a pathogen, so no antibodies are generated in case of an antigenic homologous 
exposure to the BVD virus. This super infection can result in Mucosal disease, which is 
generally fatal [77, 90, 91]. 
 Acutely infected cows can also serve as a carrier. However, they shed virus in 
considerably smaller amounts, and are infectious only for a few days [92]. Persistently 
infected cows will always produce persistently infected offspring [91, 92].  There are a 
number of test methods available, which determine the status of infection in cattle, 
which are discussed in the section below. 
1.4.3 Testing Methods 
Serum Neutralisation Test 
The serum neutralisation test (SNT) is considered the “gold standard“ for BVD 
antibody detection. It is suitable for the detection and quantification of BVD-specific 
antibodies in bovine serum. Depending on the testing format, it provides information on 
recent infections, infective status of a herd or the efficiency of a vaccination [78, 93]. In 
the SNT, a serum sample is serial diluted and each dilution is incubated with the same 
quantity of virus. If there are enough antibodies in the serum, the viruses will be 
neutralised. In order to make the neutralisation effect visible, susceptible cells are added 
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to the antibody/virus sample [93]. If the virus is successfully neutralised, the cells 
remain intact, i.e. a cytopathic effect is not recognized or an immune staining remains 
negative in case of the non-cytopathic biotype. The SNT is sensitive and specific, 
compared to the ELISA, it has, however, disadvantages regarding labour and 
dependence on cell cultures.  [92-94] 
ELISA 
The ELISA (Enzyme-linked Immunosorbant Assay) measures antigen-antibody binding 
qualitatively, and also quantitatively [95, 96]. In comparison to SNT, which only tests 
for neutralising antibodies, ELISA also tests for non-neutralising antibodies.  ELISA is 
also less complicated and is therefore used in routine diagnostics of BVD. Results are 
generally available in a few hours [97]. 
Virus Isolation 
Virus isolation in cell culture is the “gold standard” of testing for BVD virus. In this 
method, Virus is grown in certain bovine cell lines, after which the viral antigen is 
identified using immunohistochemistry [98].  Cytopathic BVD virus can be identified 
due to its destructive effect it has on cells in culture. Non-cytopathic BVD virus is made 
visible using fluorescent- or enzyme- labelled antibodies [90, 99]. Although it is a very 
sensitive method, it may give false negatives in very young calves (less than three 
months), caused by the presence of maternal neutralising antibodies. It’s therefore only 
suitable for testing older animals that are above three months. Virus isolation is also 
time consuming and quite expensive and therefore not suitable for routine diagnostics  
[99]. 
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Antigen- ELISA 
The direct testing of suspect samples via antigen-ELISA is considerably faster and 
cheaper than the virus isolation method, mentioned previously. However, virus isolation 
is about ten times as sensitive as the antigen-ELISA [100]. Also, false positive results 
are frequent and must be confirmed by a follow-up test. The antigen-ELISA is mainly 
used for testing of entire cattle herds [101, 102]. 
Real Time RT-PCR 
Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a sensitive technique to 
detect certain (RNA based) viruses, like BVD, by amplifying their genetic material 
[103]. Fluorescently- tagged primers are added to the reaction, and if the 
complementary strand (of the virus RNA) is present, the primer binds to it and the 
replication process is repeated until an end-point, which, in case of a virus positive, 
results in a fluorescent signal [104, 105]. This method is generally used for herd testing, 
and can give qualitative, as well as quantitative results. However, it is more costly than 
the ELISA, and is therefore not used in single animal testing [103, 106]. 
1.5 IBR Taxonomy and Morphology  
Infectious Bovine Rhinotracheitis (IBR) is a highly contagious, infectious disease that is 
caused by Bovine Herpesvirus-1 (BoHV-1) [107, 108]. It’s a herpesvirus, subclass 
alphaherpesvirinae, genus Varicellovirus. Other Varicelloviruses include The herpes 
zoster virus, which causes chickenpox and shingles in humans, and the pseudorabies 
virus in pigs [108, 109]. These types of viruses have restricted host ranges, and do not 
commonly or stably cross species barriers [110]. IBR was originally recognized during 
the early 1950s in feeder cattle in the western US [111].  Its main symptoms are 
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respiratory disease, and it can also cause conjunctivitis, abortions, encephalitis, and 
generalized systemic infections [112]. As with all herpes viruses, cattle infected with 
BoHV-1 may remain persistently infected, even after clinical recovery, as the virus lies 
dormant in immunoprivileged sites in the peripheral nervous system, until re-activation 
when the animal is put under stress. IBR is then active and the virus is then shed in 
secretions from the eye nose and reproductive organs [113-115].   
Herpesviruses are large, enveloped, double-stranded DNA viruses. The mature virion 
particle size ranges between 150 nm- 300 nm. Typical herpesvirus virions consist of: a 
core containing linear double-stranded DNA; an icosadeltahedral capsid of about 100 
nm diameter containing 162 capsomeres; a tegument surrounding the capsid, and an 
envelope containing viral glycoprotein spikes on its surface (see Figure 1.7) [116-118]. 
 
Figure 1.7: Structure of BoHV-1  
BoHV-1 comes in three known subtypes; BoHV-1.1b strains are associated with 
venereal disease and BoHV-1.1 and -1.2b strains are associated with respiratory disease. 
BoHV-1 subtypes have differing virulence, with BoHV-1.1 strains being the most 
virulent, and therefore causing a more severe form of the disease, and Subtype 1.2b 
strains being the least severe and the least viral shedding. BoHV-1.2b strains give 
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clinical signs of only mild rhinitis or mild vaginitis. The 1.1 strains are prevalent in 
Europe and America, whereas the 1.2b strains are the only strain that affect cattle herds 
in Australia [117-119]. 
Latent Infection 
Cattle that developed IBR due to a primary infection of BoHV-1 all become latent 
carriers of the disease. During the primary respiratory infection, virus enters the nerve 
cells of the peripheral nervous system. After recovery from the clinical signs, the virus 
is able to survive for the lifetime of the animal in these nerves, due to the 
immunoprivileged status of these cells. During this latent state, the virus is not 
replicating or disease causing [117, 119]. However, once the virus is reactivated, the 
animal will once again show clinical signs of IBR, and shed virus [116, 117]. Once 
infected, animals with latent infections will have antibodies against BoHV-1 that can be 
detected in blood and milk by suitable tests. There are rare cases an animal can be 
latently infected but have no detectable antibodies present in serum or other fluids 
tested; these are called sero-negative latent carriers. Secondary infection due to 
reactivation of the virus tends to be milder than the primary infection, due to the partial 
immunity of existing antibodies [116, 120]. There are two types of vaccinations 
available against BoHV-1, Intranasal and IM (live attenuated). However, the intranasal 
vaccine only protects short-term, and IM vaccine can cause abortion in pregnant cattle 
and is able to induce latency of the disease, due to the use of live virus. Additionally, 
vaccination will not prevent establishment of latency if an animal was previously 
infected [121-123]. 
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1.5.1 IBR Testing Methods 
Standard testing methods for the detection of IBR are similar as for BVD virus; ELISA, 
RT-PCR and Viral Isolation, as explained in Section 1.3.3. However, morphology of the 
infected cell lines in viral isolation testing differs from virus isolation test for BVD 
detection; BoHV-1 infection is characterised by grapelike clusters of rounded cells 
gathered around a hole in the monolayer; sometimes giant cells with several nuclei may 
be observed. These usually appear within three days after inoculation of the cell line. 
The most common cell line used for IBR using the viral isolation test is Madin–Darby 
bovine kidney cell line [124, 125]. 
1.6 Surface Plasmon Resonance 
The mechanism behind the optical sensing method used in the main part of this work 
(Chapter 2 and 3) is Surface Plasmon Resonance (SPR). SPR is an optical based label-
free detection method utilising a form of total internal reflectance [126]. It’s a 
phenomenon that occurs in thin conducting films at an interface between media of 
different refractive index. In a commercial SPR-2 system, the medium is the glass prism 
of the sensor chip and the sample solution, and the conducting film is a thin layer of 
gold on the sensor chip surface. 
Surface plasmon resonance occurs when the light directed to the reflecting interface 
leaks an evanescent wave field across the interface into the medium of lower refractive 
index, without actually losing net energy, see Figure 1.8  [126, 127]. The amplitude of 
the evanescent field wave decreases exponentially with distance from the surface, and 
the effective penetration depth in terms of sensitivity to refractive index is generally in 
the 100’s of nm in most systems [128]. At a certain combination between the incident 
angle and the light source, the resonant wavelength emitted excites plasmons in the 
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metal interface. As a result, a characteristic absorption of energy via the evanescent 
wave field occurs and a drop in the intensity of the reflected light can be observed 
[129]. 
 
Figure 1.8: Evanescent Field Wave in an SPR system. The incident light travels through 
the prism and is reflected off the gold surface at an incident angle. At the 
metal/dielectric interface, an evanescent waves leaks into the medium of lower 
refractive index, resulting in surface plasmon resonance. 
The conditions for the evanescent wave effect are very sensitive to the refractive index 
of the liquid within the field of the evanescent wave. Changes in particle concentration 
in the solution at the surface of the sensor chip cause changes in the refractive index of 
the solution, resulting in an SPR signal, as long as it’s within the evanescent field 
penetration depth [129-131].  
In principle, any thin metal film can be used for SPR, but the most commonly used 
material used is gold, due to its stability, biological inertness and excellent SPR 
characteristics; so in practice, an SPR sensor is usually a gold coated glass slide.   
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In biosensor applications, the binding of molecules to the sensor surface, or to 
molecules attached to the surface, changes the local refractive index and these changes 
are monitored over time. As seen in Figure 1.9,  by measuring these changes in 
refractive index information such as binding specificity, concentration of target 
molecules, kinetic rates, and affinity constants for molecular interactions can be 
determined [127, 132]. 
 
Figure 1.9 Left: Diagram of an SPR mode biological assay. The refractive index and 
therefore the incident angle changes as molecules bind to the sensor surface, resulting 
in an SPR response. Right: As the incident angle changes, due to the binding of 
biomolecules to the ligands coupled to the sensor surface, so does the RIU increase. 
Any unbound antibody dissociates and causes a slight drop in RIU until equilibrium is 
reached. The surface can then be regenerated, resulting in a sharp decrease in RIU as 
the molecules are washed away. The RIU signal is now back to its initial RIU with 
ligand coupled. From the resulting assay sensogram, the kinetics of the interaction can 
be derived by looking at the association and dissociation rates. 
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1.7 Microfluidics Sample Delivery 
Microfluidics is the handling of fluids in micron sized capillaries. The main components 
of most microfluidics system are the valves, the pumps and the sensor chip. The valves 
allow for manipulation of the fluid flow. There are two types of valves: passive valves 
that require no energy for operation and active valves that do. They control routing, 
timing, and separation of fluids within a microfluidic system and are crucial for designs 
with complex functionality [133]. The pumps of a microfluidics system are responsible 
for generating volumetric fluid movement at certain flow rates on the sensor surface and 
are used to reduce the amount of external hardware necessary to operate a microfluidic 
device. 
The sensor chip is where the chemical or biological interaction occurs and the output is 
measured. The sensors used in this work are gold-plated glass prisms. 
 
1.7.1 Sample Addressing 
The one sample delivery method that has consistently been shown to generate the 
highest quality data, and to be the most flexible in terms of potential applications when 
combined with label-free detection, is continuous flow sample addressing [134, 
135].  In this method, sample solutions are applied to the sensor surface as discrete 
volumes within a continuously flowing stream of running buffer, see Figure 1.10.  
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Figure 1.10: Sample addressing in the SPR-2 microfluidics system. A bolus of sample is 
injected over the sensor through an inlet and replaces buffer over the sensor    for the 
duration of the injection. The sample flows over the sensor and leaves through an 
outlet, while the buffer flow resumes. 
Continuous flow sample addressing provides a number of advantages, when compared 
to static assays; it provides real-time data before, during and after the binding event, 
lending itself to the determination of kinetic rates, as well as providing information 
about antibody/antigen affinity interactions. The laminar flow also ensures fresh sample 
is constantly flown over the sensor surface during injection, meaning no sample 
depletion or evaporation occurs. The assay time is also greatly reduced, when compared 
to the static diffusion assays, providing results in a matter of minutes, rather than hours. 
Microfluidics sample addressing also lends itself to multiplex assay, as the sample spot 
addressing can be controlled by selecting specific sensor spots [134, 135]. 
The SPR-2 instrument used in this work, uses a proprietary continuous flow and sample 
delivery technology technique called Hydrodynamic Isolation™ (HI™).  
In HI, guide streams of buffer solution control the size and location of sample injections 
passing over the sensor surface.  During analysis, the sample injections are introduced 
to, and evacuated from, the flow cell at specific locations relative to the target sensors. 
Sample is injected and guided through the sample inlet. It flows over the sensor spot, 
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where the assay interaction occurs. The flow is then extracted through the evacuation 
port in a continuous fashion, and replaced by running buffer, see Figure 1.11 a) and b) 
This method allows for individual spot addressing with no discernible sample leakage to 
the adjacent sensor spot. 
 
Figure 1.11: (a) and (b) Sample addressing technique over sensor spots using 
Hydrodynamic Isolation technique of the SPR-2 platform by Sierra Sensors, GmbH. 
Buffer flows on a continuous basis and is let in over the sensor through guide buffer 
inlets and is evacuated at the main flow cell exhaust. Sample is injected and enters the 
flow cell via the sample inlet, is guided over the sample spot, and extracted at the 
evacuation port. Buffer Spots can be addressed simultaneously, or individually. 
a) 
 
b) 
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1.8 Coupling Chemistry 
EDC (1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide) is a zero-length crosslinking 
agent used to couple carboxyl or phosphate groups to primary amines [136, 137]. This 
crosslinker has been used in diverse applications such as forming amide bonds in 
peptide synthesis, attaching haptens to carrier proteins to form immunogens, labeling 
nucleic acids through 5’ phosphate groups and creating amine-reactive NHS-esters of 
biomolecules [137-139]. One of the main advantages of EDC coupling is its water 
solubility, which allows direct conjugation without the need to prior organic solvent 
dissolution [139]. However, the coupling reaction has to be carried out fast, as the 
reactive ester that is formed can be rapidly hydrolysed in aqueous solutions. To increase 
the stability of this active ester, N-hydroxysuccinimide (NHS) or N-
hydroxysulfoxuccinimide (sulfo-NHS) can be used. Key parameters that should be 
controlled when using EDC are the pH (as the hydrolysis is largely dependent on it) and 
the ratio EDC/NHS [137]. Excess reagent and crosslinking by products are easily 
removed by washing with PBS or water. EDC/NHS chemistry is often used in 
covalently bonding amine containing biomolecules to a carboxyl-end group modified 
SAM (Self-assembled Monolayer) surface (see Figure 1.12). For gold surfaces, 
Mercapto-acids, which contain sulphur, create a self-assembly monolayer on the gold 
surface, by reacting with the gold thiol groups. The carboxyl end groups then create a 
covalent amide bond with the amine groups of the introduced molecules after activation 
with the EDC/NHS reaction. 
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Figure 1.12: EDC coupling of an antibody to a gold surface. A gold surface 
functionalised with a mercapto-acid self-assembled monolayer is activated via 
EDC/NHS reaction. Antibody is added to the activated surface, and displaces the 
intermediary linker from the carboxyl group via reaction with the amine group of the 
antibody, creating an amide bond. 
 
1.9 pH Optimisation and Pre- Concentration 
Pre-concentration is the determination of the optimal pH for an antibody binding to a 
surface at a certain concentration. It is a technique that aims to obtain a high local 
antibody concentration on a sensor surface to facilitate optimal immobilisation during 
the coupling step [140, 141]. The positively charged antibody is electrostatically 
coupled to the negatively charged surface of the sensor chip (or in some cases, vice 
versa), and the SPR signal response is observed [141]. In a pre-concentration 
experiment, the antibody is diluted in several immobilisation buffers of different pH’s 
that vary by a half or one pH unit, see Figure 1.13. The optimal buffer for the 
immobilisation will be the one that gives a good pre-concentration, but has the higher 
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pH. Pre-concentration is also favoured by a low ionic strength and a pH of the solution 
slightly lower than the Isoelectric point (pI) of the antibody [141, 142]. 
A low pre-concentration can give more control over the amount of immobilised ligand. 
High pre-concentration values do not guarantee that the antibody will bind in large 
amounts, due to factors such as steric hindrance [142]. Other factors like activity and 
availability of binding sites on the antibody will influence immobilisation efficiency 
also [143]. 
Generally, when the pI of a protein is known, the immobilization buffers are chosen 0.5 
pH units below the pI for pI 3.5-5.5, 1 pH unit below pI for pI 5.5 - 7 and pH 6 for a pH 
over 7 [144]. 
 
Figure 1.13: pH screening sensogram for a biological molecule from a Biacore 
protocol. In this case 4.5 is the optimal pH for ligand immobilization. Y-axial variable 
illustrates the response in resonance units (RU) after ligand injections and X-axial 
variable shows the time settled for all injections. 
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1.10 Nanoplasmonic Arrays 
In physics, a plasmon is a quasiparticle resulting from the quantisation of plasma 
oscillations. As the name indicates, surface plasmons (SP’s) are plasmons that are 
confined to surfaces. They are electromagnetic waves that are coupled to the free 
electron plasma in a metal [145]. Because of this coupling, SP waves exist only at the 
interface between a metallic film and a surrounding dielectric medium, such as water or 
buffer. The SP electromagnetic field decays away exponentially from the metal surface, 
meaning that most of its energy is confined to within ~100 nm of the surface, making its 
resonance properties very sensitive to the presence of any changes in the local refractive 
index. Since SPs are coupled to free electrons, for a given frequency, they have a larger 
wave vector than free-space electromagnetic waves, and therefore require certain 
geometries to increase the wave vector of the exciting light, such as the use of an optical 
prism or grating structures [146-148]. Surface plasmons excited via periodic arrays 
coupling on both sides of the metal film resonate through the nanoholes of a 
nanoplasmonic array as if in an optical cavity, enhancing the light transmission at 
specific wavelengths, which depends on the periodicity of the array and the dielectric 
function of both the metal and the surrounding dielectric, see Figure 1.13 [145]. Since 
more light energy is transmitted than is incident on the open hole area, this phenomenon 
is called the extraordinary optical transmission (EOT) effect [146, 147].  
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Figure 1.14: a) SEM image of a nanoplasmonic array in a gold film. b) FDTD (Finite-
difference time-domain) Simulations for a 370 nm periodicity and a 150 nm hole 
diameter nanoplasmonic array. c) Transmission spectrum from a nanoplasmonic array 
with a 390 nm periodicity and a 150 nm hole diameter [145]. 
 Nanoplasmonics have received an increase in interest in the area of biosensing, due to 
their added advantages when compared to prism-based gold sensors, including a smaller 
foot-print, lower limits of detection, denser integration, multiplexing, and collinear 
optical detection [148]. 
 
1.11 Guided Mode Resonance Sensor 
 A GMR sensor is a periodic dielectric waveguide (sometimes referred to as photonic 
crystal), in which resonant leaky modes are excited by an incident optical wave. The 
sensor’s operating spectral region is determined by the chosen grating period and 
material. The input light is reflected in a narrow spectral band whose central wavelength 
is highly sensitive to any reactions occurring at the sensor surface [149, 150]. In high-
index media, such as silicon, interesting mode-mixing effects enable operation in 
narrow spectral or angular transmission bands. This mode of operation is of particular 
interest for biosensor development. Interaction of a target analyte with a biological 
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capture layer on the sensor surface yields measurable spectral/angular shifts that directly 
identify the binding event without additional processing or the need for a reporter 
molecule, like fluorescent or chromogenic labelling, see Figure 1.14 [149, 151]. When a 
broadband light source hits a GMR sensor, a specific wavelength of light is reflected or 
transmitted at a particular angle. Since the resonance layer is polarisation sensitive, 
separate resonance peaks occur for incident TE (electric vector normal to the plane of 
incidence) and TM (magnetic vector normal to the plane of incidence) polarisation 
states [150, 152].  
 
Figure 1.15: (a) Schematic of a biological assay on a GMR sensor. (b) Binding events 
occurring at the sensor surface produce resonance-peak shifts [149]. 
 
GMR sensors can be functionalised with standard surface chemistries, such as 
silanisation, to covalently attach capture molecules, like antibodies, to detect protein 
targets out of an analyte solution. This sensor technology is broadly applicable to 
medical diagnostics, drug discovery and development, industrial process control and 
environmental monitoring [151]. 
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1.12 Scope of Thesis 
The scope of the thesis is to develop label free optical diagnostic assays on different 
platforms towards low cost point of care diagnostics. The aim is to detect BVD and IBR 
virus for application in veterinary diagnostics, as a rapid, simultaneous on-site 
diagnostic method for the detection of these two prevalent infectious diseases in cattle; 
and C1q protein as a biomarker from a panel of biomarker for the rapid, on-patient 
detection of a biomarker signature for pancreatic cancer, a difficult to diagnose and 
lethal cancer, for medical diagnostics in humans. Table 1.1 shows a table with the 
biomolecules used and the detection methods performed. 
Platform: SPR Nanoplasmonics GMR 
Capture Molecule: BVD and IBR virus C1q scFv antibody; 
BVD virus 
C1q scFv antibody, 
BVD virus 
Protein Detected: BVD and IBR 
antibodies 
C1q protein; BVD 
antibodies 
C1q protein; BVD 
antibodies 
   Table 1.1: Platforms used as part of this work and Biomolecules detected 
Chapter 2 explores the development of a simultaneous virus assay for the detection of 
antibodies in response to viral infection by BVD and IBR in bovine serum on the SPR-2 
platform. There is currently no simultaneous detection of these prevalent bovine 
infectious diseases. Testing is costly and time consuming and involves tissue samples 
collected from the herd and send to a veterinary laboratory for ELISA testing. This 
process is timely and expensive. The aim of this work is to provide low-cost rapid, on-
site evaluation of disease status and therefore protect herd health in a cost effective 
manner. 
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In Chapter 3, we discuss the fabrication and characterisation of nanoplasmonic arrays 
on a gold film. The purpose of the nanoplasmonic arrays is to offer a potential POC 
substrate for POC testing. Nanoplasmonic arrays are substrates that have garnered much 
interest, due to their suitability for label free diagnostics. They are easily integrated into 
an optical system, have a small footprint and show a potential to be more easily 
multiplexed. This work moves the platform to a real-time system towards a POC 
diagnostic platform. After establishing its suitability as a biosensor, C1q scFv antibody 
clones as a biomarker to pancreatic cancer are screened on the SPR-2 platform, and then 
transferred to the nanoplasmonic array format. Nanoplasmonic arrays are used in both 
optical/microfluidic benchtop hybrid system and static assays, to detect C1q antigen in 
buffer and serum. The detection of BVD antibodies in buffer and serum are also 
performed using the nanoplasmonic array static assays. 
Chapter 4 describes the fabrication and characterisation of Guided Mode Resonance 
(GMR) sensors on a SiN substrate as a possible low cost option for a point of care 
diagnostic biosensor. Two different modes of biomolecule attachment are explored; 
adsorption and covalent coupling after functionalising the GMR surface by silanisation. 
Static C1q detection assays are performed to determine the suitability of the GMR as 
sensor for the detection of pancreatic cancer biomarkers; Static BVD virus assays are 
also performed to explore virus detection using this platform. Finally, the GMR is 
transferred to the benchtop hybrid system, to carry out C1q detection on this platform 
and determine the suitability of this substrate for microfluidic assaying. GMR sensors 
are currently not employed as POC substrates, however, our research shows that they 
would be suitable substrates for real-time, low cost rapid sensors for POC systems.  
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2.1 Introduction 
Surface Plasmon Resonance (SPR) is a method of real-time, rapid label-free detection 
that monitors changes of refractive indices between biomolecular interactions on 
plasmonic (gold) surfaces. SPR occurs when light strikes an electrically conducting 
surface at the interface between two media (see Chapter 1, Section 1.6) [1, 2]. 
SPR was first described by R.M Wood in 1902 at Johns Hopkins University (Baltimore, 
USA) [3]. He noticed that when he shone polarised light onto a metal-backed diffraction 
grating, a pattern of unusual dark and light bands appeared in the reflected light. In the 
fifties more experimentation was done on electron energy losses in gasses and on thin 
foils. Pines and Bohm suggested that the energy losses were due to the excitation of 
conducting electrons creating plasma oscillations or plasmons [4, 5]. Further research 
revealed that the energy loss resulted from excitation of a surface plasma oscillation in 
which part of the evanescent, electric field extended beyond the metal boundary. 
Therefore, the presence of any film or contaminant on the metal surface affects the 
surface plasmon oscillation [5]. This effect was later described in terms of excitation of 
electromagnetic ‘evanescent’ waves at the surface of the metal, and in the 1970s these 
waves were described as a means to study ultra-thin metal films and coatings [6, 7]. 
There have been two major approaches to optical excitation of surface plasma waves: (i) 
attenuated total reflection in prism coupler-based structures and (ii) diffraction at 
gratings structures [8]. The application of surface plasma waves excited by the 
attenuated total reflection method for sensing has been pioneered by Nylander and 
Liedberg [9]. Particularly because of its relative simplicity, this method has been widely 
applied for characterization of thin films and biochemical sensing. 
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In the 1980s, surfaces plasmon resonance (SPR) and related techniques exploiting 
evanescent waves were applied to the interrogation of thin films, as well as biological 
and chemical interactions [10, 11]. These techniques allow the user to study the 
interaction between immobilised receptors binding with analytes in solution, in real 
time and without labelling of the analyte. By observing binding rates and binding levels, 
there are different ways to provide information on the specificity, kinetics and affinity 
of the interaction, or the concentration of the analyte  [12, 13]. 
The testing of biological samples for diagnostic purposes using SPR has been gathering 
more popularity due to its rapid and label free real-time analysis that is able to handle 
multiple samples [13, 14]. Biacore (GE Healthcare) is the current world leader, holding 
up to 90 % of the market share, but with a boom of new SPR technology companies 
recently emerging on the market, it has become a popular, highly competitive 
technology in diagnostics application  [15-17]. 
The agricultural industry in Ireland is one of its major economical sources of income 
and the largest single employer [18]. Cattle farms for Dairy and Beef are a major factor 
for Irish agricultural revenue. Bovine disease are one of the major factors for economic 
losses in this industry, and apart from prevention, rapid diagnosis of bovine illnesses is 
one of the factors to prevent spread, and therefore loss, as well as being a factor of 
concern for the welfare of the animals. Two major bovine diseases that are currently 
affecting the Irish cattle herd health are BVD and IBR (see Chapter 1, sections 1.7 and 
1.8) [19-22]. 
Bovine Viral Diarrhoea (BVD), caused by BVD virus (BVDv) is a highly contagious 
viral disease of cattle [23]. Successful BVDv eradication in several Scandinavian 
countries has been achieved through the use of ‘test and cull’ protocols involving 
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removal of persistently infected (PI) individuals [24]. In January 2013, a mandatory 
national eradication programme for BVD, coordinated by Animal Health Ireland (AHI), 
was introduced in the Republic of Ireland [24, 25]. Currently, the scheme involves ear-
notch BVD virus testing of all new-born calves in order to identify PIs for culling, as 
required  [25, 26].  The scheme is due to move into the surveillance phase of testing 
based on the progress of the scheme so far in halving the number of PIs being born 
annually.  Surveillance is most often based on checking for the presence of anti-BVD 
antibodies in bovine serum or milk (individual or bulk) [26, 27]. Bulk milk testing is an 
inexpensive and practical means of determining herd antibody status but has three 
significant drawbacks in terms of national surveillance in Ireland.  Firstly, bulk milk 
analysis for BVDV antibodies does not readily distinguish between vaccinated and 
unvaccinated herds for all vaccines.  Secondly, BVD antibody readings may reflect 
historical rather than current viral herd status. Thirdly, this method doesn’t identify 
individuals or non-lactating cattle [26-29]. 
Infectious bovine rhinotracheitis (IBR) is a disease caused by the BoHV-1 Virus. It is 
characterised by acute inflammation of the upper respiratory tract [27].  BoHV-1 
infection can also sporadically cause abortion in cattle.  It has a prevalence of ca. 70% 
in the Irish cattle population [27, 30]. BoHV-1 infection affects animal health and 
productivity causing significant economic losses to cattle producers. Its main 
significance is as a barrier to the export of live cattle to other regions or countries within 
Europe, which have already eradicated the disease [30, 31].  It is also a significant 
disease for pedigree herds placing animals into artificial insemination (AI) stations. 
Bulls destined for use in AI are not permitted to have any antibodies to BoHV-1 [31, 
32]. To prevent confusion, IBR will be used in this work to describe both BoHV Virus 
and the disease IBR itself. 
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The diagnostic methods applied for both IBR and BVD virus are Virus neutralisation 
assays and ELISA (see chapter 1, sec 1.3.3). The drawback of both these methods is 
mainly that they are slow, require labelled probe molecules and don’t allow 
multiplexing, i.e. test for more than one agent. In this work, we developed a rapid label-
free multiplex assay towards point-of-care application for IBR and BVD, potentially 
enabling simultaneous analysis for the detection of these infectious diseases in bovine 
serum on site. This would allow for a rapid and cost effective diagnosis, when 
compared to the current method of detection, ELISA, and potentially prevent viral 
outbreaks within a herd that could lead to economic loss, due to the ability of immediate 
intervention and prevention of disease spread due to the significant decrease of the 
diagnostic time frame. 
2.2 Materials and Reagents 
100 mM Dulbecco’s PBS (Phosphate buffered saline) pH 7.2 and HCl were purchased 
by Sigma Aldrich.  SPR-2 Affinity Sensors-Amine, Sodium Acetate Buffers, Amine 
coupling kit (1-ethyl-3-(3-dimethylaminopropyl) carbodimide hydrochloride (EDC), 
ethanolamine-HCl pH 8.5; N-hydroxysuccinimide (NHS)) and Glycine pH 2 were all 
purchased from Sierra Sensor GmbH.  SPR-2 commercially available sensor chips 
functionalised with Mercaptohexadecanoic acid were routinely employed.   Deionized 
water (18.2 MΩ cm) was obtained using an ELGA Pure Lab Ultra system. C1q Protein 
and C3 Protein were purchased from Sigma Aldrich. Anti- bovine IgG, Murine anti- 
Human IgG Antibody, Fc specific; Human IgG (whole Molecule), Murine Anti-Human 
IgG Antibody, Fab’ specific; Jackson Immunolab. BVD and IBR virus and monoclonal 
antibodies BVD specific to the envelop glycoprotein (Erns) of the virus were purchased 
from Animal and Plant Health Agency (APHA Scientific, UK). All reagents were used 
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as received.  Positive and negative bovine serum samples were provided by Teagasc 
biobank (Moorepark, Ireland). ELISA kits used were Qiagen cattletype BHV1 gB Ab 
Test and IDEXX IBR gE Ab Test.   
2.3 Experimental 
SPR Sensor preparation 
To pre-condition the sensor alternative injections of 2 x 25μl HCl (0.1M, 2min) (both 
spots), and then 2 x 25μl of Elution Buffer (1M NaCl/10mM, NaOH, 2 min) over both 
sensors was undertaken. Pre-concentration was then undertaken by dispersing IgG 
antibody are in either sodium acetate immobilisation buffer pH’s 4, 4.5, 5.0, 5.5  and 
6.0, and in PBS pH 7.2 .   
SPR Assay development 
Sensor surfaces are first activated using eight minute injection (200 µl at 25 µl/min) of 
EDC/NHS then by an eight minute injection of antibody (200 µl at 25 µl/min).  Capture 
antibody either 7 µg/ml of rabbit anti-murine antibody; 7 µg/ml rabbit anti-bovine were 
then covalently coupled to the sensor surface Following this step, any remaining 
unreacted carboxyl groups are blocked with Ethanolamine- HCl (100 µl at 25 µl/min).  
Specific analytes of interest (bovine IgG 14 µg/mL rabbit anti-bovine IgG or 14 µg/mL 
were then injected (200 µl at 25 µl/min) and the RI change monitored. Non-specifically 
bound target was removed by rinsing in buffer (1 minute, 25 µl/min).  Following an 
assay, bound target molecules were removed by flowing either 0.1 M HCl, 0.1 M 
NaOH/NaCl or pH 2 Glycine (10 seconds, 25 µl/min) over a sensor to regenerate the 
capture antibody surface. All assays were performed at ambient temperature. 
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For BVD and IBR virus detection, a 106 cell solution of each virus was diluted to a final 
concentration of 7x103 cells/ml of virus; equalling 7 µl/ml of virus solution. Following 
this step, any remaining unreacted carboxyl groups are blocked with Ethanolamine- HCl 
(100 µl at 25 µl/min).  200 µl virus solution was flown over the sensor for 8 min 50 µl 
of analyte (serum positive, pure antigen in buffer or serum negative) was injected over 
the probe material captured on the sensor surface. The regeneration step was performed 
with pH 2 glycine, 8 µl for pure antigen in buffer, and 10 µl for serum, to ensure all 
residues were removed. 
ELISA assay development 
The ELISA procedure was carried out to provide a benchmark for the SPR-2 results, as 
followed: The first well was left empty for a blank. 50 µL dilution buffer N9 was 
dispensed into the remaining wells while 50 µL negative control was dispensed into two 
wells.  50 µL positive control was then dispensed into two wells. Finally, 50 µL of each 
sample was dispensed into the remaining wells.  The contents were homogenised using 
DIASource ELISA Plate Shaker – Incubator DIA4000 at 400rpm then incubated for 24 
hours at 4 °C.  The wash buffer was diluted 1:20 with DI water and the conjugate 1:100 
in dilution buffer N1 (as per Qiagen kit). The Plate was washed with 300 µL wash 
buffer, five times using ELISA Plate Washer DIA3000 (DIASource). 100 µL of dilute 
conjugate was dispensed in each well and left incubate at room temp for 30min. The 
Plate was washed with 300 µL wash buffer, five times using DIASource ELISA Plate 
Washer DIA3000. 100 µL of TMB substrate (chromogenic substrate) N9 was dispensed 
in each well and left incubate at room temp for 20 min in the dark. 100 µL of stop 
solution N3 was dispensed in each well. The plate’s absorbance was read at 450 nm 
using DIASource ELISA Plate Reader DIA2000, with the first well acting as blank. 
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2.4 Results and Discussion 
The first task of this work was to commission a new SPR-2 analytical instrument and 
develop general assay protocols that could be adapted to the different capture molecules 
used later in this work. Assay may be broken down into three parts: (i) preconditioning 
step to ready the gold sensor, (ii) preconcentration step for antibodies as capture probes 
to enhance binding by finding optimal pH conditions and (ii) target analyte probing to 
find the optimal range of protein concentration for the interaction, the limit of detection 
(LOD), perform kinetic analysis, and detect disease markers probed for in serum 
samples. 
The first step of performing a SPR-2 assay was to precondition the sensor. This serves 
to condition the Mercapto molecules functionalised on the sensor surface in order to 
make them more accessible for the ligand by exposing the carboxyl group at the end of 
the Mercaptoacids for antibody coupling. To precondition the sensor, four alternating 
injections of twice each NaOH/NaCl (100mM/10mM) and HCL (100mM) are 
performed, respectively, for 1 min at a flow rate of 25 µl/min. Figure 2.1 shows an SPR 
sensogram of a typical pre-conditioning step.  The two peaks observed at time ~100 s 
and ~590 s are due to the injection of the NaOH/NaCl which has a higher refractive 
index than PBS (the running buffer).  By contrast the two minima observed at ~350 s 
and 825 s are attributed to HCl injection (which has a lower refractive index than PBS).   
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Figure 2.1: SPR sensogram showing a typical preconditioning step.  The two peaks 
observed at time ~100 s and ~590 s are due to the injection of the NaOH/NaCl while the 
two minima observed at ~350 s and 825 s are attributed to HCl injection. 
 
 
Figure 2.2: SPR sensogram showing a typical pre-concentration step.  Peaks for 
electrostatic binding at different pH’s are shown .    
Pre-concentration was then undertaken to determinate of the optimal pH for an antibody 
at a certain concentration. Figure 2.2 shows a typical SPR sensogram for IgG fab 
specific whole antibody. This approach aims to obtain a high local antibody 
concentration on the sensor surface to facilitate optimal immobilisation during the 
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coupling step [33, 34]. Several immobilisation buffers of different pH’s were employed. 
From Figure 2.2, the optimal buffer for the immobilisation which gave a good pre-
concentration was pH 4.5 which was then used for subsequent assays.  Acetate buffer 
was selected as the optimal pH pre-concentration buffer due to its low ionic strength. 
The pKa of sodium acetate are 4.76 (acid) and 9.25 (basic). In comparison, PBS which 
is used as a running buffer and also for the pH 7 preconcentration injection has a pKa of 
7.2.  The buffer pH 4.5 solution was slightly lower than the Isoelectric point (pI) of the 
antibody [33, 35].  The broad and intense RI peak shows that the antibody was 
successfully bound to the surface in a usable manner.  A sharp peak would indicate that 
the antibodies had aggregated at the sensor surface and would not be available for 
subsequent binding events.  It is important to also consider other factors like activity 
and availability of binding sites on the antibody will influence immobilisation efficiency 
also  [36, 37] when selecting the optimal pH.   
Assay development: buffer 
Following determination of the optimum pH value for each antibody in this manner, 
antibodies were covalently attached to the sensor surface using EDC/NHS coupling 
chemistry.  Following covalent attachment, unreacted carboxylic acid sites were 
blocked Ethanolamine- HCl. Ethanolamine is an effective blocking agent, as it masks 
any carboxyl groups left exposed after EDC/NHS activation on the gold sensor surface 
after the antibody coupling step, due to the hydrophilic hydroxyl groups present in the 
molecule, therefore reducing the potential for non-specific binding. After the blocking 
step, bioassays were then undertaken.  Figure 2.3 shows a typical assay using a 
commercial murine IgG anti-human IgG sandwich assay in PBS buffer, pH 7.2 
characterised using the optimised SPR approach.  The assay was run in the 
recommended (sensor 1 - blue) order where the Fc specific antihuman IgG mab was 
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used as the capture (immobilised) antibody using the fab specific antihuman mAb as 
secondary antibody and in the reverse (sensor 2 - red) order where the fab specific 
antihuman mAb was used as the capture (immobilised) antibody and the Fc specific 
antihuman IgG mAb was used as the secondary antibody.   
 
Figure 2.3: Example for a SPR-2 sensogram;screenshot showing murine anti- human 
IgG sandwich assay. The sandwich assay was run in the recommended forward format 
(blue), and in reverse format (red).The y axis shows RIU, the x axis shows time in 
seconds. The diagram shows the corresponding stage in antibody assay. 
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Figure 2.4: Assay repeat of reverse format assay, comparing with recommended 
format,murine anti- human IgG sandwich assay in Figure 2.3, showing repeat antigen 
injection of human IgG over antibody coupled sensor. The sandwich assay was run in 
the recommended forward format (red), and in reverse format (black).A steady signal 
with good response is observed for the Fab down (reverse) format after each cycle of 2 
µg/ml human IgG. Detection with the Fc antibody results in a sizeable response. In 
comparison, Fc antibody down (recommended) format shows very little response. 
Detection with Fab antibody results in a minimal signal. 
 
Both assays were run in parallel.  Concerning sensor 1 (blue) a refractive index increase 
at ~ t = 1,500 was observed and may be attributed to the covalent coupling of Fc 
specific anti-human IgG mab to the sensor surface.  A very slight increase in refractive 
index was also observed at t = 2,500 seconds. This increase was attributed to binding of 
the target human IgG (4 µg/mL) to the immobilised probe.  The refractive index 
increases at t = 3,000 s and t = 3,400 s may be attributed to two injections of fab specific 
antihuman mab secondary antibodies.  The decrease in refractive ndex observed at  t = 
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4,200 s was attributed to removal of the antibody following the injection of HCl.  
Concerning sensor 2 (red) the refractive index increase at ~ t = 2,000 may be attributed 
to the covalent coupling of fab specific antihuman mab capture antibody.  At t = 2,500 
seconds there is a much higher increase in refractive index, compared to sensor 1, when 
human IgG is injected over both sensors.  This increase indicates that fab specific 
antihuman mab serves as a better capture antibody.  A further increase in refractive 
index at t = 3,400 s was attributed to binding of the Fc specific antihuman IgG mab used 
in this case as the secondary antibody.  These results were in contrast to the suppliers 
instructions for the assay and would not have been detected using an ELISA approach.  
The poor performance of the Fc specific antihuman IgG mab may arise from structural 
conformal changes in the antibody once it has been bound to the gold surface possibly 
arising from the electrostatic charges.  Consequently, for our work undertaken using this 
model sandwich assay on gold nanoplasmonic sensors (see chapter 3) the assay was run 
in reverse format.  Figure 2.4 shows a repeat of a murine anti-human IgG assay, with 
repeat cycle injections of antigen. Again, the reverse Fab down format shows a steady 
and good signal response, whereas the recommended Fc down format shows very little 
signal. 
 
During the SPR qualification process, other antibodies assays were also investigated. A 
commercial rabbit anti-murine IgG sandwich assay (whole molecule) was also assessed 
and again needed to run in the reverse format.  This understanding was critical as the 
rabbit anti-murine IgG sandwich assay was used to characterise the surface of the 
nanoplasmonic arrays initially (cf. chapter 3).   
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Assay development: serum 
Following assay development in buffer solution, work was also undertaken to qualify 
the SPR sensor in serum.  A bovine IgG antibody assay (whole molecule) was to test for 
IgG levels in cow serum.  Pre-conditioning and pre-concentration experiments as 
described previously were also undertaken for bovine IgG. A commercial kit was 
obtained and the assay run in the vendor specific order, with 7 µg/ml rabbit anti-bovine 
(RAB) IgG, Fc specific, acting as the capture molecule followed by two minute serum 
injection (pure bovine IgG), and finally a two minute injection of rabbit anti-bovine 
IgG, Fab’ specific secondary antibody.  Figure 2.4 shows assays run in in forwad and 
reverse order. As can be seen in Figure 2.4, the RAB Fab’ specific antibody molecule 
had a much higher affinity for its antigen than the proposed Fc specific capture 
molecule. The RIU difference was about 100 RIU between the antibody/antigen 
interactions.  Clearly, this higher RIU would lead to greater sensitivity with lower limits 
of detection achievable.   
 
Figure 2.5: Rabbit anti- Bovine antibody assay, using the recommended format on 
sensor 1(red), and in the reverse format on sensor 2. As can be seen at t = 4000 s, the 
difference in the assay entire is approx. 100 RIU greater for the reverse format run on 
sensor 2 (black). 
 
 
 
 
EDC 
Fc spec IgG Ab 
Fab spec IgG Ab 
Ethanolamine 
Bovine Serum 
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Figure 2.6: Rabbit anti-bovine assay repeat.  
Both assays were run in parallel.  The refractive index increases at ~t = 5 s and ~t = 
2,200 s may be attributed to injections of EDC/NHS and Ethanolamine-HCL, 
respectively.  For sensor 1 (red), a refractive index decrease at ~ t = 800 was observed 
and is due to the lower refractive index of the antibody/buffer solution.  An increase in 
refractive index is visible following the end of the injection at ~ t = 1,500 and may be 
attributed to the covalent coupling of Fc specific rabbit anti-bovine IgG antibody to the 
sensor surface. The increase in refractive index was also observed at t = 3,200 seconds 
was attributed to binding of the target bovine IgG (2% bovine serum) to the 
immobilised probe.  Concerning sensor 2 (black) reverse assay format, the refractive 
index increase at ~ t = 1,600 may be attributed to the covalent coupling of fab specific 
rabbit anti-bovine capture antibody.  At t = 3,800 seconds there is a  higher increase in 
refractive index, compared to sensor 1, when 2% bovine serum is injected over both 
sensors.  This increase indicates that fab specific rabbit anti-bovine antibody serves as a 
better capture antibody for Bovine IgG in serum.  These results were again in contrast to 
the suppliers instructions for the assay and may not have been detected using an ELISA 
approach.  As with the murine anti-human IgG assay of Figure 2.3, the poor 
performance of the Fc specific anti-bovine IgG antibody may arise from structural 
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conformal changes in the antibody once it has been bound to the gold surface possibly 
arising from the electrostatic charges.  SPR 2 sensors were regenerated using glycine 
between different serum samples and a return to the original baseline was observed in 
all cases.  Glycine was found to be more successful in removing serum as well as pure 
buffered antigen, compared to HCl and NaOH/NaCl. 
 
Bovine Viruses BVD and IBR assays 
Following successful demonstration detection of the model Bovine IgG antibody in 
serum, the optimised protocol was applied also to detection of bovine virus.  In this 
work however, no pre-concentration step was carried out for the virus coupling. This 
was to avoid any potential change in conformation of the antigenic target sites, as well 
as the possible cloaking of the epitopes during coupling, should the binding site be close 
to the epitope, e.g., a change in pH could result in structural changes in the epitopes.  
Another difference in this work was whole virus was used as the probe material aimed 
at detecting antibodies being expressed by an animal to the disease infection.  The 
viruses used were whole particle BVD and IBR. 
ELISA 
All bovine serum samples (provided by Teagasc) tested using the SPR-2 were first 
benchmarked against ELISA (Qiagen kit for the BVD assays and IDEXX for the IBR 
assays), to confirm and validate the results BVD, Samples 6266, 6327, 6323, 6390, 
6399, 6462 and 6392 tested positive using ELISA, and sample 452, 770, 771, 521 tested 
negative; see Table 2.1. 
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Sample  BVD Result Tyndall BVD Results 
Teagasc 
6266 Positive Positive 
6327 Positive Positive 
6323 Positive Positive 
6390 Positive Positive 
6392 Positive Positive 
6399 Positive Positive 
6462 Positive Positive 
452 Negative Negative 
521 Negative Negative 
770 Negative Negative 
771 Negative Negative 
Table  2.1: ELISA results for BVDv serum samples 
Concerning IBR ELISA results positive samples were 83, 84, 331, 461, 6462, 46 and 
6390, and the negative samples were 82, 232, 233, 234 and 451; see Tables 2.1 and 2.2. 
Both the BVD and IBR sample results consequently provide a known disease status 
cohort. 
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Sample IBR Result Tyndall IBR Results Teagasc 
82 Positive Positive 
83 Negative Negative 
84 Negative Negative 
233 Negative Negative 
234 Negative Negative 
331 Positive Positive 
451 Negative Negative 
452 Negative Negative 
461 Positive Positive 
631 Positive Positive 
6323 Positive Positive 
6390 Positive Positive 
6462 Positive Positive 
Table 2.2: IBR ELISA test results using a commercial test kit.  
The negative control mean must be greater than or equal to 0.8 and the positive control 
should have a S/N % less than 20% for the assay to be valid. The S/N % is calculated by 
dividing the sample by the negative control mean and multiply by 100. 
S/N% ≥ 60%: Negative; S/N 51–59%: Suspect; S/N ≤ 50%: Positive 
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2.4.1 SPR-2 BVD and IBR Antibody Detection in Bovine Serum  
Prior to virus based assays a sensor preconditioning step was again carried out as 
described previously above, see Figure 2.1. In this work, whole virus was covalently 
coupled to the carboxylated gold surface using EDC/NHS coupling as described in the 
experimental section.  The viruses served as the biological capture molecules target 
disease specific antibodies expressed by an infected (or previously infected) animal.  
Figure 2.7 (a) shows a typical SPR sensogram for a BVD assay where 0.5 % serum 
samples from three cattle were injected sequentially onto a sensors surface.  A glycine 
regeneration step was undertaken between each injection.  Figure 2.7 (b) shows a 
zoomed view of the rectangular section shown in Figure 2.7 (a). Sample 452 shows a 
significant response in the SPR sensogram at t = 4,000s.  However, this is in contrast to 
the ELISA results whereby sample 452 was identified as being serum negative.  Clearly, 
these results point to either (i) increased sensitivity of the SPR method (ii) or to, more 
than likely, significant non-specific adsorption being present.  Non-specific adsorption 
is considered as the shape of the observed peaks do not reflect a kinetic binding profile 
as seen, for example, in red curve t = 3,400 in Figure 2.5.  To confirm that the observed 
response were due to non-specific binding rather than a positive result, the samples were 
sent to a licenced commercial BVD test laboratory (The Enfer Group) to undertake 
BVD assay.  The results of these analyses were in agreement with the ELISA results 
Table 2.1 strongly suggesting that the increase in refractive index arose from non-
specific adsorption.  The is most likely as the serum samples used were crude, i.e whole 
blood, as it would reflect point-of care situation in the field.  Of note, samples 6323 and 
6399 were identified as positive in the ELISA study and did show a higher  
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Figure 2.7: a) BDV virus assay with 0.5% bovine serum and b) zoom of section in (a). 
The Samples injected are 452, 6323 and 6399, respectively. 452, is a BVD negative 
serum sample, but still elicits a significant response 
 
It is not surprising that non-specific adsorption occurred since, on visual inspection, the 
serum samples as supplied were turbid and contained a lot of cellular debris which 
could easily have “stuck” to the sensor. Since blocking chemistries based on for 
example, milk powder, are less compatible with flow through sample delivery methods, 
it was decided to use a dilution approach instead [38-40].   
 
 
Virus
Ab sensing
452
6323 6399
(a) (b) 
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Figure 2.8 Sensogram showing a close up of injections of BVD sera diluted to 0.2 %. 
Samples  770, 6462, 452, 521, 771, 6327, 6390, 6392 and 6399, respectively. Positive 
and negative samples can be discerned (denoted by “+” for positive samples and “-“ 
for negative samples).  Refractive index increases are observed for negative samples. 
 
Figure 2.8 shows diluted (0.2 %) bovine serum injected over BVD coupled sensor.  
Again a sensor regeneration step was undertaken between each injection.  Although 
there is non-specific adsorption visible for the negative samples (770, 452, 521 and 771) 
a clear discrimination between serum positive and serum negative is beginning to 
emerge.  The shapes of the positive peaks are beginning to exhibit kinetic rather than 
adsorption profiles.  Figure 2.9 (a) shows a typical sensogram for BVD samples diluted 
to 0.1% with PBS with clear difference between positive and negative samples.  Figure 
2.9 (b) shows a background sensogram obtained when 0.1 % BVD negative sample is 
injected over a sensor in the absence of BVD capture virus molecules.  An increase of 
dissociation time was also implemented (from 400 to 800 sec from the previous assay in 
Figure 2.8), to increase the removal of adsorbed material. The residual signals for the 
negative samples are approximately 100 RIU, which is appropriately low enough to be 
considered background noise.  Control assays were carried out to determine the amount 
- +       - - - +     +      +     +
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of signal that was observed due to non-specific adsorption entailed a number of 
injections of 0.1% bovine BVD serum over the surface of a sensor that had the 
EDC/NHS activation step, and the Ethanolamine blocking step, but no virus was 
coupled to the sensor surface. As can be seen the refractive index value of 100 RIU 
tallies well with the negative samples in Figure 2.9 (a).  Consequently a cut-off set at 
100 RIU (akin to a titre value in ELISA) between positive and negative samples could 
be established.  It is important to note however that this is not a robust value as only a 
small number of samples were available to be assayed.  To accurately define a cut-off 
value over 1,000 positive and negative samples would need to be measured and a 
statistically correct value obtained.   
 
Figure 2.9: (a) BVD assay with 0.1% serum. Samples 770, 6266, 6299, 452 and 521. 
Positive and negative samples can be clearly discerned. Cut-off point of 100 RIU 
identifies between positive and negative (b) non-specific adsorption when 0.1 % serum 
is injected over a non-modified sensor exhibiting a refractive index increase to 100 
RIU. The positive samples are clearly above the cut-off point, whereas the serum 
negative samples are below the established threshold established in (b). 
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In a similar manner, IBR whole virus was immobilised onto a sensor surface and diluted 
(0.5%) serum samples injected.  Figure 2.10 shows a typical sensogram for two IBR 
positive sera sample numbers 83 and 84 (identified through the ELISA study) and two 
negative sera sample number 82 and 232.  A sensor regeneration step was carried out 
between each injection.  The two positive samples exhibit a significant response at t = 
2,500 and 3,600, respectively.  However the shapes of these peaks also suggest non-
specific adsorption.  This is confirmed as both samples 82 and 232 (serum negative) 
both show significant increase in refractive index.   
 
Figure 2.10: Sensogram for 0.5 % bovine serum over IBR virus. Sample 83, 84 (IBR 
positive) and 82, 232 (IBR negative), respectively. As can be seen from the positive 
response for the IBR negative samples, the non-specific adsorption (NSA) is quite high. 
To ascertain a working serum concentration that enabled the determination of anti- IBR 
antibody status of the serum samples, IBR serum samples were diluted to a range of 
dilutions, until a final concentration of 0.05% in PBS injected over IBR virus coupled 
sensor surface showed an emerging kinetic profile. Figure 2.11 shows a typical assay, 
where positive and negative disease status can clearly be discerned. The positive 
samples are well above the cut-off points and the negative sample is clearly below it. At 
t= 4400, the sample negative 451 has signal of ca. 80 RIU. When deducting from the 
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reference control injection (without virus coupled to the sensor surface) of Figure 2.11 
(b) in the same manner as for the BVD serum assays performed in Figure 2.10 (one 
could deduct half, as it is half the concentration, so ~50 RIU), the result correlates with 
the ELISA control tests. At t= 1600 and t= 3300, a high RIU identifies the two serum 
positive samples as IBR antibody positive, in accordance with the ELISA control test. It 
can therefore be concluded that at a concentration of 0.05% serum, IBR antibody status 
in cattle can be identified.  
 
Figure 2.11: (a) IBR 0.05%: IBR positive 0.05% bovine serum over sensor. Samples 83, 
6390 and 451. Samples 83 and 6390 are positive, 451 is negative and elicits negligible 
response. Cut-off point of 100 RIU identifies between positive and negative (b) non-
specific adsorption when 0.05 % serum is injected over a non-modified sensor 
exhibiting a refractive index increase to approximately 100 RIU.   
 
Stability 
For Figure 2.12, a typical assay of IBR was run at a 0.1% serum dilution and plotted as 
a histogram (purple). An increase in dissociation time from 400 to 800 seconds was also 
implemented, to observe if the residue that prompts the positive signal for the serum 
negative samples could be washed away over time. For the negative samples 234 and 
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451, there is non-specific binding apparent still, but there is a clear difference between 
positive and negative samples at this concentration with the increased dissociation time. 
The positive samples 6462 and 461, the refractive index observed is much higher than 
the negative sample, confirming an antibody positive status. Figure 2.12 (green) shows 
the 0.1 % assay repeat for IBR virus/ bovine serum assay after three day of storage in 
the fridge, with virus coupled. The sensor used to run the assay and shown in purple 
was regenerated (analyte removed by glycine injection) and the sensor with the virus 
coupled was stored in the fridge for three days, to determine stability and robustness 
after storage and the ability to still elicit antibody response. The assay was then repeated 
after running an injection delay of 3200 sec, to equilibrate the sensor to room 
temperature, and to make a direct comparison to the primary assay. The resulting 
histogram (green) is comparable to the histogram of the primary assay (purple), 
showing good stability and repeatability of the assay after storage.  
 
Figure 2.12: Histogram of IBR 0.1% repeat injection on SPR-2 platform: purple) 0.1 % 
bovine serum assay of serum samples 234 and 451 (negative) and samples 6462 and 
461 (positive). (green) The repeat of that assay, after three days storage of the sensor 
coupled virus at 4 degrees Celsius in the fridge. 
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2.5 Conclusion 
In this chapter we establish operating procedure for a new SPR instrument.  These were 
developed using commercial sandwich assay kits of murine anti-human IgG and rabbit 
anti-bovine IgG assays. It was found that the assays operated more efficiently in reverse 
format as compared to the vendor instructions, suggesting that the surface charge of 
gold had an effect on the antibody configuration. These data fed directly in to work 
presented in chapter 3. Following successful qualification of the SPR system, new label-
free assays were developed for two bovine diseases, namely Bovine Viral Diarrhoea 
(BVD) and Infectious Bovine Rhinotracheitis (IBR). The assays for the detection of 
BVD and IBR antibodies in bovine serum were developed with the intent of a future 
simultaneous diagnostic assay for those common, debilitating bovine diseases at point-
of-care. It was quickly established that whole blood was raising the issue of non-
specific binding using the SPR microfluidics. To investigate further, the serum 
concentrations were dropped to 0.5% initially, which still showed a lot of non-specific 
binding, and then 0.2% and subsequently 0.1%, with an increase of dissociation time 
also to see if the residue would be removed over time. BVD containing serum shows 
some shaping of an assay at 0.2 %, with positives and negatives starting to have higher 
and lower RIU. At 0.1%, this becomes even clearer further. IBR positive serum still 
showed inaccuracies in disease status at 0.2%, and to some degree at 0.1 %, but 
difference in RIU peaks between positives and negatives can be observed at this stage. 
An injection of 0.1 % serum of both BVD and IBR positive serum was performed as a 
control over a bare sensor, i.e a sensor that had no virus coupled to the surface, but had 
an EDC and blocking step, to determine how much non-specific binding there 
potentially is. This was then used as a reference to establish a cut-off point between 
positive and negative serum samples. Interestingly, non-specific binding was not a 
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factor with the BVD assay run on the nanoplasmonic sample shown in chapter 3 and 4, 
even though higher concentration of serum were used for both positive and negative 
sample runs. This is probably due to the delivery mechanism, as the surface material 
and chemistry are the same; the microfluidics delivery appears to be more prone to the 
non-specific binding of the cellular debris, unlike the diffusion mechanism of the static 
assays, which makes it less vulnerable to false positives. Stability testing was also 
performed, where sensors with the virus coupled where stored in the fridge for three 
days, and the assay repeated to observe any potential loss of activity. The assay 
performed as expected, and no discernible loss in activity was observed. The SPR 
results where compared to the ELISA assay performed as control. It was found that the 
label free bioassay was found to be a suitable, more rapid detection method for IBR and 
BVD antibody in serum, when compared to ELISA. 
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3.1 Introduction 
As previously shown in chapter 2, label-free detection is a powerful technique that 
allows for real-time, sensitive, rapid detection of biomolecules [1-3]. However, it comes 
with its own drawbacks. It is a lab based method that requires trained personnel to 
operate expensive equipment, which makes it quite a high cost method to employ [3, 4]. 
It also requires relatively high sample volumes, when compared to some of the labelled 
methods, such as microarrays [5-7]. New approaches are required that address these 
issues, to make label free sensing more cost effective, user friendly, high throughput 
and reduces the volume of sample required. Below is a table of some of the current 
popular technologies on the market.  
System Manufacturer Industry Benchtop Test/hour Analysis 
time 
Sample 
Vol. 
Targets 
AIA-360 Tosoh Bio. 
Inc. 
DIA Yes 36 > 1 min >200ul Biomarkers 
ABL90 FLEX Radiometer 
America, Inc. 
DIA Yes 30+ > 1 min >65ul Biomarkers 
SQiDman SQI 
Diagnostics 
DIA Yes 200+ >30 sec >200l Biomarkers 
IMMULITE 1000 SIEMENS DIA Yes 120 >30 sec >200ul Biomarkers 
Triage MeterPro Alere DIA Yes <10 15 min >50ul Biomarkers 
Spotchem EZ ARKRAY DIA Yes 60 8 min >200ul Biomarkers 
BLItz PALL Corp LS Yes 20 1 min >100ul Biomarker 
& protein 
sam@x Saw 
Istruments 
LS Yes 12 1 min >200ul Biomarker, 
protein & 
cell 
Phast-ID Consortium LS & 
DIA 
Yes 60+ 1 min >15ul Protein & 
Biomarker 
Table 3.1: Popular label free technologies currently on the market. DIA denotes 
Use in diagnostics; LS stands for use in Life science. 
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To date, these technologies have been used in the Diagnostics and Life science market, 
but face one or all of the previously above mentioned drawbacks. 
The work in this chapter aims to address some of these problems by aiming to provide a 
low cost, effective biosensor using nanoplasmonic arrays. Here, we explore the potential 
for application of these sensors with “real world” probe material, including viruses, 
whole antibodies and scFv antibodies for detection in buffer or serum. SPR 
instrumentation methods were employed for initial assay development, followed by 
transfer to the new sensor format. The fabrication, simulation and characterisation of the 
nanoarrays is discussed, as well as the detection of the target analyte and the suitability 
of the arrays as label free biosensors. 
3.2. Materials and Reagents 
The materials and reagents used in this section were Acetone, Trichloroethylene, IPA, 
3-Mercaptopropionic Acid (MPA), 12- Mercaptododecanoic Acid (MDA),  
Cysteamine-HCL, (+)-Biotin N-hydroxy-succinimide ester, Strepdavidin, DMSO, 
Phosphate Buffered Saline (PBS), 100 mM Dulbecco’s PBS (Phosphate buffered saline) 
pH 7.2, HCl, 99.5% NaCl, Mercaptododecanoic acid (MDA), Mercaptopropionic acid 
(MPA), C1q Protein and C3 Protein were all purchased from Sigma Aldrich. Anti- 
bovine IgG, Murine anti- Human IgG Antibody, Fc specific; Human IgG (whole 
Molecule), Murine Anti-Human IgG Antibody, Fab’ specific; Jackson Immunolab. 
Gold film nanoarrays were fabricated in-house. SPR-2 Affinity Sensors-Amine, Sodium 
Acetate Buffers, Amine coupling kit (1-ethyl-3-(3-dimethylaminopropyl) carbodimide 
hydrochloride (EDC), ethanolamine-HCl pH 8.5; N-hydroxysuccinimide (NHS)) were 
all purchased from Sierra Sensor GmbH.; scFv C1q antibody was provided by Lund 
University. Deionized water (18.2 MΩ cm) was obtained using an ELGA Pure Lab 
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Ultra system. BVD virus and monoclonal antibodies BVD specific to the envelop 
glycoprotein (Erns) of the virus were purchased from Animal and Plant Health Agency 
(APHA Scientific, UK). All reagents were used as received.  Positive and negative 
bovine serum samples were provided by Teagasc biobank (Moorepark, Ireland). 
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3.3 Experimental 
3.3.1 Nanoplasmonic Arrays 
Metal evaporation 
To fabricate nanohole arrays, a 5 nm Cr film was first deposited on a clean Si substrate 
by metal evaporation (Temescal FC-2000 E-beam evaporator), followed by evaporation 
of 50 nm thick Au layer.  
 
FIB milling  
The sample was then loaded into the QuantaTM 3D 200i DualBeamTM Focused Ion 
Beam (FIB). The ion beam was focused on an area near to where the arrays will be 
milled, as when focusing the beam the gold surface is damaged by the ions. Individual 
60 µm × 60 µm periodic nanohole arrays with a pitch of 450 nm were fabricated on the 
sample (30 kV beam voltage, 300 pA beam current, 1 pass, a defocus of 14 µm and 
dwell time of 14 ms). As the beam current controls the quantity of Ga+ ions, lower 
currents produce a smaller spot size but mill at a much slower rate while higher currents 
make a bigger hole, faster. 300 pA was found to give holes of about 80 nm in diameter 
in a reasonable time. 80 nm pore size was used, because it showed to leave enough light 
through to give a sizeable spectral peak, while allowing for a reasonable milling time. 
At higher currents the hole size was too large and irregular; unsuitable for sensing 
applications. To make 110 nm holes the 300 pA beam was defocused slightly to 
increase the size of the nanohole. 
Lift off  
The 50 nm films were then freed from the underlying Si substrate by wet etching the 
underlying chromium layer (Chrome Etchant Lodyne, Grower Chemicals Ltd.) for 10 
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minutes. The chip was then removed and immersed into deionised water where the Au 
film floated on the surface (due to surface tension of the water meniscus) while the Si 
substrate sank to the bottom. Using this approach the highly fragile gold films were 
easily freed from the silicon substrate in a contactless manner that prevented any 
damage occurring to the film. Finally, a glass microscope slide was immersed under the 
gold nanostructured film and used to lift the film from the water and dried for 24 hours. 
 
Simulations 
Finite Difference Time Domain (FDTD) simulations were performed using JFDTD3D 
(version 2.0) program [13] available under the General Public License (GPL). The 
program is based on a 3-D, parallel FDTD implementation using the Message Passing 
Chapter 2 56 Interface library. The code was run on 8 nodes, each node having 2 
Opteron CPUs (2.6 GHz, 4 GB RAM). 
 
Computational Volume 
 
Figure 3.1: Schematic of the simulation setup 
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The grid spacing in each spatial dimension was 5 nm.  The computational grid was 
chosen to be 450 × 450 × 1600 𝑛𝑚3. The extra lengths in the z directions allowed the 
resolution of Raleigh-Wood's anomalies, if present. Periodic boundary conditions (450 
nm) in the x and y directions were applied to simulate an infinite square array. Perfectly 
Matching Layers (PML) boundary conditions were imposed in the z direction in order 
to avoid reflections from the edges of the computational window. The setup was 
modelled by a 50 nm Au film with a 650 nm thick glass substrate (𝜀𝐺𝑙𝑎𝑠𝑠 = 2.31 𝜀0) and 
a 900 nm dielectric (air/water) (𝜀𝑑) superstrate (see Figure 3.1). In the plane of the film, 
the nanohole was centered in the middle of the square (𝑥0 = 𝑦0 = 225 × 10
−9) and the 
equation used to define the circle is, 
 (𝑥𝑝𝑜𝑠−𝑥0)2+(𝑦𝑝𝑜𝑠−𝑦0)2
(55×10−9)2
= 1   
 
 
  
To confirm that the nanoplasmonic arrays would be suitable for immunoasays, Finite 
Difference Time Domain Simulations undertaken (by Dr. Daniel Jones of the 
Nanotechnology Group). In order to simulate the excitation source, a Gaussian damped 
sinusoidal pulse (having a frequency content of 1 to 6 eV) was launched from the glass 
side and simulation run (for 200 × 10−15 𝑠𝑒𝑐) in the time domain. Total transmission 
spectra were obtained by Fourier transforming the simulated electric and magnetic 
fields on a surface above the holes and constructing the surface integral of the outward 
Poynting vector. 
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Figure 3.2: Shows the far field transmission spectra for an array with a pitch of 450 nm 
and nanoholes of 110 nm 
 
In order to evaluate the refractive index sensing capabilities of these samples, far-field 
transmission spectra were simulated using a layer with refractive index of 1.45 to 
simulate a layer of biomaterials. Layers of 10 nm to 50 nm (every 10 nm) were 
simulated and the spectra shifts with each increase in the layer. The R2 of this simulation 
is 0.996, and not 1, due to the inherent nature of the FDTD algorythm.   
 
 
Figure 3.3: Shows 0.3520 nm shift per 1nm layer and an R-Square = 0.996 
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The minimum dip in the region 630-650 nm was measured and the shift plotted against 
the layer thickness. The nanoplasmonic array simulations, fabrications and structural 
characterisations were done by Dr. Daniel Jones of the Nanotechnology group and 
described in detail in the thesis “Nanofabrication towards Biophotonics”. 
 
Optical images 
 Optical micrographs were acquired using a calibrated microscope (Axioskop II, Carl 
Zeiss Ltd.) equipped with a charge-coupled detector camera (CCD; CoolSNAP cf, 
Photometrics).  
 
Transmission spectra  
Transmission spectra of samples were collected using a combination of an Olympus 
IX71 inverted microscope and an Acton SP2300i spectrograph equipped with a 300 
gr/mm grating and a 20 µm slit (resolution of ~0.1 nm.) 
 
Optical Characterisation 
 A 100 W Halogen white light source was used to illuminate the sample, with the 
incident angle of light within 10 degrees with respect to the normal of sample. All 
recorded transmission spectra were normalized with respect to a glass substrate. A 
simple microfluidic cell was constructed by gluing two pieces of 0.15 mm thick cover 
slip on either side of the adsorbed gold film (using UV curable glue) on a microscope 
slide. A third cover slip was bridged over these pieces of cover to form a lid of the cell. 
Chapter 3: Bioassays on Nanoplasmonic Arrays 
94 
 
Surface tension forces from the fluid under investigation were sufficient to hold the lid 
in place during experiments.  
 
Figure 3.4: (a) Scanning electron micrograph of a portion of a nanopores array with 
diameters of 110 nm and a pitch of 450 nm.  Inset: high resolution image showing four 
nanopores.  (b) schematic showing the optical setup 
 
 SEM  
Scanning electron microscopy (SEM) images of self-assembled nanohole arrays were 
acquired using a field emission SEM (JSM-6700F, JEOL UK Ltd.) operating at beam 
voltages between 5 and 10 kV. 
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AFM  
The topography of both pristine and biologically modified gold films were characterized 
using a calibrated atomic force microscope (AFM; Dimension 3100, Veeco Instruments 
Inc.) in tapping mode with commercial tapping mode probes (MP-11100, Veeco 
Instruments Inc; typical radius of curvature ~ 10 nm and front/side cone angles of 
15º/17.5º, respectively). No processing was applied to data apart from the usual 
background plane subtraction.  
  
 
Figure 3.5: Optical Microscope, SEM and AFM images, respectively, of the plasmonic 
nanoarrays. 
 
Gold cleans 
The clean procedure was to first solvent clean by immersing the chip in acetone, 
trichloroethylene, acetone, IPA and DI water, respectively, each for 10 min. The film 
was then dried under a stream of Nitrogen and placed in a UV ozone cleaner (AFM Tip 
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Cleaner, Bioforce Laboratory) for 20 min at both ambient temperature and oxygen 
concentrations. 
 
Bulk refractive index sensing 
NaCl solutions were prepared by dissolving 0, 8, 12, 16, and 21g in 100 ml of deionized 
water to form solutions with refractive indices of 1.333, 1.347, 1.354, 1.361 and 1.370; 
respectively. 
 
 
Surface Characterisation 
The following procedure was used for the Biotin/Strepavidin gold surface 
charachterisation assay: First, the gold substrate was cleaned using the solvent 
UV/ozone clean procedure. This was followed immediately by imersion in a beaker of 
6.2 mM Cysteammine Hydrochloride (in DI water) for 72 hours, to functionalise with a 
SAM layer to run the Biotin/Strepavidin assay. After 72 hours, the sample was removed 
from the beaker and dried under a Nitrogen stream. 12 mg of Biotin ((+)-Biotin N-
hydroxy-succinimide ester)) was dissolved in 2 ml of DMSO and the solution dropped 
on the gold chip to cover it entirely. This was left for 45 min. 1mg of Strepavidin was 
dissolved  in 4 ml of PBS buffer, dropped on the gold sample and left for 20 min. The 
sample was rinsed with PBS and carefully dried under Nitrogen steam between each 
step. AFM’s were taken after clean, Cysteamine–HCL, Biotin linking and Strepavidin 
incubation steps. 
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3.3.2 SPR assay development 
Preconditioning 
As discussed prior in Chapter 2,  a preconditioning step is performed to condition the 
sensor for the assay by alternating injections of 2 x 25μl HCL (0.1M, 2min) (both spots) 
and with 2 x 25μl of Elution Buffer(1M NaCl/10mM NaOH, 2min), over both spots. 
 
Preconcentration 
For the preconcentration assays, 14 µg/ml of scFv anti-C1q antibody were prepared in 
10mM Sodium acetate buffers of pH 4.5,5.0,5.5,6.0 and PBS pH 7.2. 25µl of each 
varying pH solution was injected over the sensor surface at a flow rate of 25µl/min. 
Excess Antibody was removed with 8-10µl HCL, at the same flow rate. 
 
Assay Procedure for Antibody Coupling 
Assays are performed over the commercial SPR- 2 sensors (Sierra Sensors), which are 
functionalised with Mercaptohexadecanoic acid (MHDA). An injection of 200 µl of 200 
mM ethyl-(N’,N’-dimethylamino)propylcarbodiimide hydrochloride (EDC) and 25 mM 
N-hydroxysulfosuccinimide (NHS) was first performed  to activate the carboxyl groups 
of the MHDA. This was followed by an injection of 200 µl of a 14 µg/ml C1q scFv 
Antibody in pH 4.5 sodium acetate solution (as determined by preconcentration step). 
The activated carboxyl groups react with the amine group of the antibody to form a 
covalent (amide) bond. The surface was subsequently blocked with an injection of 100 
µl of ethanolamine, to prevent non-specific binding. After the antibody coupling step, a 
Chapter 3: Bioassays on Nanoplasmonic Arrays 
98 
 
number of assay procedures were performed to determine antibody performance, 
explained in the next steps. The flow rate of injection was kept at 25 µl/min throughout 
all SPR-2 assays performed. 
 
Limit of Detection Assays 
Four injections of 50 µl each of C1q protein were performed in concentrations of 2 
µg/ml, 0.5 µg/ml, 0.2 µg/ml and 0.1 µg/ml. Each protein injection cycle was followed 
by a regeneration step using 0.1M HCl. 
 
Calibration Curve 
A calibration curve was performed by injecting six concentrations of pure C1q protein 
in PBS buffer of 2 µg/ml, 3 µg/ml, 4 µg/ml, 6 µg/ml, 8 µg/ml and 10 µg/ml over the 
sensor with the coupled anti-C1q antibody from the previous experiment. The results 
were plotted and data analysed to determine the antibody/antigen kinetics. 
Selectivity Assays  
For the selectivity assays, three injections of 50 µl 0.5%, 1% and 5% human serum were 
performed over the C1q antibody coupled sensors. A 0.1 M HCl regeneration step was 
performed between each serum injection. 
Affinity/Off-Rate Testing 
The antibody/antigen affinity interaction was determined by injection of 2 μg/ml C1q 
protein in PBS buffer over the coupled antibody sensor. A second injection of 2 μg/ml 
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C1q protein buffer was made, with a dissociation time of two hours implemented, to 
observe the off rate of the interaction. 
 
Stability/Robustness Testing 
To ascertain viability and robustness of the antibodies after repeated testing, three 2 
μg/ml injections of C1q protein in PBS buffer were made over the coupled antibody for 
two minutes. HCl (8 μg/ml) was injected to remove Antigen between injections. 
 
3.3.3 Nanoplasmonic Array Assays 
For the static assays, after the cleaning of the self-assembled gold film, the chip was 
immersed in a 5 mM Mercaptododecanoic acid solution (MDA in 99% Ethanol, Sigma 
Aldrich) for 24 hours to assemble an ordered monolayer of MDA on the gold surface. 
After 24 hours, the chip was removed from the MDA solution, carefully rinsed with 
ethanol and dried under a nitrogen stream. The gold surface was then activated by 
pipetting a 60 μl aliquot of EDC/NHS for 30 min onto the gold film. A 60 μl aliquot of 
capture antibody of i) 14 μg/ml murine monoclonal (mAb) anti human IgG antibody 
(whole molecule,) in sodium acetate buffer, pH 4.5, for the characterisation assays. ii) 
20 μg/ml anti-C1q scFv antibody in pH 4.5 sodium acetate buffer for the C1q detection 
assay iii) 7 μl of BVD virus in PBS for the BVD detetction assay were then deposited 
on the gold surface of a sensor and allowed to covalently couple for two hours at room 
temperature. This was followed by a blocking step with Ethanolamine-HCl, pH 8.5, for 
30 minutes. Gold films were then subsequently rinsed with 0.1 M PBS (pH 7.2) and 
dried under a nitrogen stream. A 60 μl aliquot of target antigen in i) PBS or ii) serum, or 
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iii) (non-target) control was dropped on the gold surface and allowed to incubate for 2 
hours at ambient temperature. The gold film was then rinsed in 0.1 M PBS to remove 
excess antigen and dried in a N2 stream. Transmission spectra were recorded in 0.1 M 
PBS buffer following each biological addition step. Smoothing of the spectral data was 
performed by using a convolution algorithm with 10 data points in Matlab. 
 
Custom- Built Optical/Microfluidics Hybrid System Assays 
The static assays used in the microscope system were subsequently transferred to the 
custom built setup. The nanoplasmonic array sensor was first prepared by immersion in 
5mM MDA for twenty four hours for SAM assembly. The sample was then docked onto 
the sample holder in the custom system. The functionalised gold surface was activated 
by a 60 µl injection of EDC/NHS, which was followed by a 60 µl C1q scFv Ab (20 
µg/ml) and blocked with Ethanolamine-HCl. A subsequent 60 µl Injection of 60 µl of 
2% human serum in PBS was then performed. The flow rate was kept at 20 µl/min 
throughout all assays, and 0.1M PBS was used as running buffer. 
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3.4 Results and Discussion 
3.4.1 C1q Antibody Assay development  
Clone screening 
Assay development for the Nanoplasmonic Arrays was first carried out on the SPR-2 
platform (see chapter 2). That is because this method provides visibility of the assays 
being performed, as well as allowing for the characterisation of the biomolecules used. 
This was particularly important as the scFv antibodies used in this work were research 
antibodies produced by a project partner, and required rigorous testing and development 
of optimal assay conditions prior to transfer onto the nanoarray platform. An important 
step was to screen the available antibody clones for the most efficient capture molecule. 
A desirable antibody profile includes good on/off rate, high sensitivity, high selectivity 
and high affinity to the target protein [8-10]. A number of clones of the same molecule 
would be tested, compared and the final selection made. Experiments carried out to 
make the selection included pH optimisation, pure antigen in buffer runs at varying 
concentrations, LOD assays, serum assays and selectivity assays with non-target 
protein. Stability and robustness was also screened for, with repeating assays. The scFv 
were found to be robust and retained their functional capabilities after being repeatedly 
assayed over several days at high capacity. 
 
Preconditioning 
Figure 3.6 shows a typical preconditioning step over an SPR sensor. NaCl/NaOH peaks 
are approx. at t = 100 and t = 570. HCl peaks are at approx. t = 350 and t = 820. The 
high RI responses of the NaCl/NaOH peaks are due to the high refractive index of the 
Chapter 3: Bioassays on Nanoplasmonic Arrays 
102 
 
solution, compared to the PBS running buffer. The dips in RI when HCL is injected 
over the sensor are due to the lower refractive index of the solution, when compared to 
the PBS running buffer. 
The preconditioning step serves to condition the MDHA groups on the functionalised 
gold surface, as well as removing any possible MDHA excess on the surface, and 
therefore enhancing the antibody coupling performed during the first phase of the assay. 
After preconditioning, normal assay procedure can follow. 
 
Figure 3.6: Sensor preconditioning step. NaCl/NaOH peaks are approx. at 100 and 570 
RIU. HCL peaks are at approx. 350 and 820 RIU. 
 
Preconcentration 
The preconcentration step serves to obtain the pH that enables optimal antibody 
coupling to the sensor surface (see Chapter 1, section 1.8 and Chapter 2). The optimum 
pH was chosen based on the greatest signal response of antibody, due to the amount of 
antibody bound to the surface via electrostatic interaction (see chapter 2). Figure 3.7 
shows a typical preconcentration step for C1q at 14μg/ml. The optimum pH was found 
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to be 4.5, as the broad curve with a high peak shows a better electrostatic interaction 
with the gold surface than at other pH values.   
 
 
Figure 3.7:  pH screening of scFv antibody anti- C1q clone ; 14 μg/ml. The selected pH 
for the clone is pH 4.5 sodium acetate (10 mM) 
 
Limit of Detection Assays  
The first procedure to evaluate the scFv antibody clones was to determine the Limit of 
detection (LOD) for that antibody on the SPR-2 platform. The example in Figure 3.8 
shows a typical assay for C1q(1) [C1 q clone 1]. Four injections of 50 µl each of C1q 
protein at varying concentrations were performed and the results observed. a) Shows an 
increase to 360 RIU at t = 1,000 sec for 2 µg/ml over the sensor. The initial spike of the 
injection is due to the high on-rate of the interaction. The antigen quickly binds to the 
capture antibody, and excess washes rapidly away. Equilibrium is quickly reached 
between antibody and target antigen, as indicated by the plateau after end of injection, 
showing a high affinity for C1q protein by the antibody.  b) Shows the injection for 0.5 
µg/ml of C1q antigen at t = 2,300 sec. The RIU at that concentration is approximately 
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100. c) Shows an increase to approximately 80 RIU at t = 3,800 sec for a concentration 
of 0.2 µg/ml. d) Shows an increase of approximately 30 RIU at t = 6,000 sec for 
injecting a concentration of 0.1 µg/ml over the gold sensor.  Each injection of protein 
was followed by a regeneration step using 0.1M HCL. The LOD of detection for C1q is 
~0.2 µg/ml (0.5 nM). 0.1 µg/ml is also seen to elicit a positive signal, but not high 
enough to not be considered background noise. The LOD value established for C1q is 
an observational value only,  statistical analysis was not performed, as it was outside the 
scope of this work.  
 
Figure 3.8: Detection of Protein in pure buffer. 4 x 50 µl l/2min injection of C1q 
Antigen were performed in a serial dilution. The blips during antigen dissociation time 
(the feature at (b) at 3000 sec, for example) are software artefacts. 
 
Antibody Calibration Curve Assay 
The next step in clone characterisation involved performing a calibration curve of the 
antibody/antigen interaction, to determine the affinity and off/on rates of the antibody 
[10]. Figure 3.9 shows a typical sensogram for a calibration curve assay, where six 
 
 
a) 
b)                c)                d) 
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increasing concentrations of pure PBS buffered C1q antigen were injected over the gold 
sensor. a) Shows the injection for 2 μg/ml. At t = 600 sec, the refractive index rises to 
250 RIU, due to the C1q antibody binding to the target C1q protein. b)  Shows an 
increase to 400 RIU at t = 1,300 sec for 3 μg/ml after injection of C1q protein over the 
sensor. c) Shows the injection of 4 μg/ml at t = 2,600 sec, with an increase to 500 RIU 
after antigen injection over the sensor. d) At t = 4,600 sec shows an increase to 800 RIU 
after a 6 μg/ml injection of C1q was performed. The injection for e), at t = 4,600 sec 
shows that 8 μg/ml of C1q protein results in an increase of 1100 RIU. d) at t = 5,300 
sec, 10 μg/ml C1q protein injected over the surface resulted in a RIU increase of 1400. 
The results were taken to perform kinetic analysis of the antibody, shown in Figure 3.10 
and Figure 3.11. 
 
Figure 3.9: Example concentration injections for calibration curve of C1q scFv 
antibody. C1q target protein in PBS buffer are a) 2 μg/ml , b) 3 μg/ml, c) 4 μg/ml, d) 6 
μg/ml, e) 8 μg/ml and f) 10 μg/ml. 
 
 
 
 
 
a)         b)            c)        d)            e)      f)  
f) 
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The results from Figure 3.9 were taken, and the values at equilibrium plotted to give a 
calibration curve, shown in Figure 3.10. As can be seen, there is good linearity of the 
interaction, with a R2 value of 0.996 
 
Figure 3.10: Peak RIU vs concentration plot of C1q Antigen calibration Curve shown 
in Figure 3.9. The R2 value is 0.996. 
 
The results of the calibration experiment in Figure 3.9 were also processed to determine 
the kinetic values of the antibody/antigen interaction. Of particular interest is the KD 
constant, which shows affinity in the low nanomolar range for this particular 
interaction. KD is the equilibrium dissociation constant, which is used to evaluate and 
rank the affinity of bimolecular interactions. Affinity is the strength of binding of a 
single molecule to its ligand. The binding of an antibody to its antigen is a reversible 
process, and the rate of the binding reaction is proportional to the concentrations of the 
reactants. At equilibrium, the rate of antibody/antigen complex formation is equal to the 
rate of dissociation into its components. The measurement of the reaction rate can be 
used to define an affinity constant (1/KD). In short, the smaller the KD value, the greater 
the affinity of the antibody for its target. Most antibodies have KD values in the low 
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micromolar (10-6) to nanomolar (10-7 to 10-9) range. High affinity antibodies are 
generally considered to be in the low nanomolar range (10-9) with very high affinity 
antibodies being in the picomolar (10-12) range [8, 10]. The obtained values for C1q 
scFv antibody show that it is in the low nanomolar range and can therefore to be 
considered a high-affinity antibody. This is confirmed by the LOD experiment of Figure 
3.8, which shows that the detection limit of C1q antibody is approx. 0.5 nM. 
 
Figure 3.11: Kinetic data for C1q antibody was plotted using the Langmuir Equation 
using SPR-2 onboard software 
Ka Kd KA 
1.064E +0004 -3.634E-004 -3.414E-008 
Table 3.2: Values for kinetic data of Figure 3.11 for C1q(1) scFv antibody. Ka = 
association rates  Kd = dissociation rates  KA =association binding constant  
 
Selectivity Assay 
To determine selectivity of the anti-C1q protein for the target protein in a complex 
protein mixture, three injections of 50 µl human serum in PBS at a) 0.5%, b) 5% and c) 
1% concentrations were performed. Figure 3.12 shows a typical assay for a selectivity 
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assay using human serum. It can be seen that C1q protein was easily detected in 0.5% 
human serum, showing at t = 600 sec a refractive index increase of 200 RIU after C1q 
antibody bound C1q protein from the complex protein solution. At t = 3,000 sec, an 
increase in signal for the 1% serum shows more available analyte with an RIU of 300 
after serum injection over the sensor. At 5%, the high abundancy of the target shows 
saturation of the binding sites, seen at t = 1,800 sec, which is shown by the continued 
decrease in signal after injection during the dissociation time from the initial RIU of 
700, where excess target protein that is unable to bind leaves the sensor surface. 
 
 
Figure 3.12: Selectivity of C1q scFv Ab was tested with a mixed protein sample. Serum 
was diluted in PBS (pH 7) buffer to three concentrations; a) 0.5%, b) 5%, and d) 1%, 
respectively. 
 
Affinity Testing 
Figure 3.13 shows a typical affinity assay test. At t = 2,800 sec, an initial control 
injection of 2 μg/ml was made, to compare the RIU value to the affinity test injection to 
be made. The sensogram for the control injection shows a refractive index of 
 
a)               b)                     c) 
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approximately 400 RIU. At t = 5,000 sec the 2 μg/ml injection was repeated, but this 
time a two hour dissociation time was implemented. The RIU increased again to 400, 
and as can be seen in Figure 3.13, the level of C1q protein on antibody, after two hours, 
showed very little dissociation, indicating a strong affinity between C1q antibody and 
Antigen. 
 
Figure 3.13:  A two minute injection of C1q 2μg/ml was performed over the sensor, 
followed by a second injection of C1q, but this time with a dissociation time of two 
hours. A 400 RI step increase was observed. 
 
Stability Test Assay 
Stability and robustness of the antibodies were tested after three days of high intensity 
assays, to determine if the antibodies would still be viable to perform accurate test 
assays. Figure 3.14 shows a typical assay, where three 2 μg/ml injections were made 
over the coupled antibody for two minutes (at t =10 sec, t = 1,000 sec and t = 1,800 
sec), and compared to each other and also to the 2 μg/ml in the previous clone screening 
assay tests. As can be seen in Figure 3.14, the RIU for the 2 μg/ml are all approximately 
400 RIU, which is also the consistent with the RIU values at that concentration for the 
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previous tests. The Antibody shows no degradation in performance and viability, as 
shown by the consistency of peaks between the injections, as well as when compared to 
2 μg/ml injections of the previous experiments, which all have a value of approx. 400 
RIU. 
Figure 3.14: Stability and robustness of the scFv anti-C1q  antibody testing after 
running three days of high-intensity assays. Blips in the middle of the dissociation phase 
are software artefacts (at approx. 400 sec for first injection, for example). 
3.3.3 Nanoplasmonic Assay Development 
Following the development and optimisation on the SPR-2 platform, the bioassays were 
subsequently transferred to the Nanoplasmonic array format. 
Prior to performing the bioassays, the nanoarrays were characterised by looking at 
transmission spectra after using different concentrations of NaCl solutions. Salt solution 
was applied to the sensor surface and a spectrum was taken in the Picoquant. The 
solution was rinsed and a higher concentration was applied and a spectrum taken. That 
was repeated a number of times. The shift observed was bulk shift, as it was the result 
of the refractive index change due to the increase in salt concentration [11]. To 
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characterise the peak shift due to binding to the sensor surface, a Biotin/Streptavidin 
assay, which is a well-established characterisation assay, was undertaken. This assay is 
hardy, and is a high affinity, stable interaction [12-14]. It involved functionalising the 
gold surface with Cysteamine- HCl, followed by covalently coupling esterised Biotin to 
the amine groups of the functionalised surface. This is subsequently incubated with 
Streptavidin. Atomic Force Microscopy images (AFM’s) were taken before (clean gold) 
and after Cysteamine self-assembly, after Biotin coupling, and after incubation with 
Stretavidin, respectively. This served to measure the surface roughness of the gold 
surface, for evidence of an increase of a molecule layer after each step [15]. After the 
surface was characterised and a clean established (see section 3.2), the bioassay was 
finally transferred to the nanoplasmonic arrays. 
Furthermore, after establishing a static assay on the nanoplasmonic arrays, the assay 
was transferred to a hybrid system containing a custom build optical system and 
microfluidics set-up.  
 
Figure 3.15: Gold film containing nanoarrays during antibody incubation.  
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Cleans and Surface Characterisation 
Prior to depositing any biomaterial on gold substrates it is essential to have a pristine 
clean surface [12, 13, 16].  Previous work in the group had encountered a problem when 
it came to cleaning thin gold structures using both oxygen plasma and mixed acid cleans 
such as piranha.  Both of these cleaning approaches resulted in pitting and roughening 
of the gold surface or in some cases lifting the structures from the underlying silicon 
substrate. Consequently, it became essential to develop a clean that was suitable for the 
self-assembled gold substrate to a) remove any dirt and residue without damaging the 
gold surface; b) lend itself to SAM surface modification. 
A thorough literature search was undertaken, and cleans were narrowed down to a small 
number of methods including UV ozone, mixed solvent clean and which were assessed 
[16-21].  
A clean that combined of acetone, Trichloroethylene (TCE), Acetone, IPA and DI 
water, respectively, was selected following assessment. Acetone was employed to break 
down organic compounds; TCE to remove any grease off the surface; IPA to remove 
any residue of acetone from the surface; and DI water to remove any final residues. The 
samples were then dried with N2. A 20 minute UV/ozone step was then employed to 
break down any remaining organic residues and to hydroxylate the surface (generate 
OH groups) which is required for SAM assembly using carboxyl-based thiols and EDC 
coupling techniques [22]. The characterisation of the gold surface was done using a 
combination of contact angle measurements and AFM (Atomic Force Microscopy). 
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Figure 3.16 (a) AFM and contact angle after solvent clean of gold substrate. (b) AFM 
and contact angle after solvent clean and UV ozone for 20 min. 
 
The initial characterisation of the SAM layer was performed with MPA (3-
Mercaptopropionic Acid), using 10 mM of MPA dissolved in DI water. Drops were 
placed in different areas of the surface, to get a representative measure of hydrophilicity 
of the sample surface. As can be seen in Figure 3.17, the surface hydrophilicity has little 
variance, meaning every process step is achieved evenly, covering the entire area. 
Measurements were done between each step.  
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Figure 3.17: contact angle measurements of gold substrate, after solvent clean, 
UV/Ozone treatment, and MPA modification. The average value for the contact angle 
after solvent clean was 73.5 (black line); After UV ozone, 56.3 (red line) and after MPA 
modification, 18.7 (blue line). 
After establishing a cleaning method, the surface was subsuquently investigated for 
suitability of modification with biomolecules. For surface characterisation, the well 
established  model system of Biotin- Streptavidin was chosen. This system is hardy, 
high affinity, as well as one of the strongest non-covalent interactions known with a 
dissociation constant (Kd) on the order of ≈10−14 mol/L.  
 
 
After solvent clean 
After UV/Ozone  
After MPA modification 
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Figure 3.18: Surface characterisation using biotin/strepavidin model assay. AFM’s 
were taken after clean gold, cysteamine-HCL functionalisation, biotin coupling and 
Strepavidin modification. 
Using the AFM method, surface roughness between each step of the assay were 
investigated, to observe an increase layer of molecule, and therefore the suitability of 
the developed clean and the assay method. As can be seen from the AFM’s in Figure 
3.18, the first image is clean gold with a roughness of 1.6. After Cysteamine-HCL 
modification, it becomes slightly less rough with 1.26. Cysteamine-HCL is a small 
molecule (~3nm) [23], and a drop in roughness is expected with the assembly of a 
regular cysteamine “carpet”. Coupling the esterised Biotin to the Cysteamine resulted in 
a large increase in roughness, to 2.4, which was followed by another  increase to 3.2 
after Strepavidin incubation. The roughness increase shows the  addition of a layer in 
each assay step, which is a good indication of the suitability of the developed clean. 
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Nanoplasmonic Bioassay Characterisation 
After the characterisation and simulations procedures of the gold surfaces, and the clone 
characterisation descibed in the previous sections, the transfer to the nanoplasmonic 
array platform was undertaken, to establish a biosensor using the plasmonic nanoarrays. 
To confirm simulation results for the nanoplasmonic arrays as a suitable, label free 
biosensor, an antibody assay was performed using an antibody model system and 
spectra taken between each incubation step. Furthermore, AFM images were taken also 
at the first and the last step of the assay.  
Figure 3.19 (a) shows a typical AFM image of a gold nanoarray modified with a MDA 
(12-mercaptododecanoic acid) layer. Figure 3.19 (b) was taken at the end of the full 
assay, after incubation with the protein target and the secondary antibody. A distinct 
increase of thickness and roughness can be observed between the images. The 
difference between the initial spectrum and the final shift was approx. 7 nm, see Figure 
3.19 (c). 
The assay run was murine anti-human mAb (Fc specific) as primary antibody; the 
antigen detected was human IgG (whole molecule) and the secondary antibody was 
murine anti-human IgG (Fab’ specific). Figure 3.20 shows a repeat of this assay. 
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Figure 3.19: Antibody Sandwich Assay on plasmonic nanoarrays. a) AFM’s were taken 
after MDA modification, and after b) secondary antibody incubation. c) Shows the 
corresponding spectra, after primary antibody coupling (black); after antigen (red); 
and after secondary antibody (blue). A clear red shift between each step can be seen. 
 
Figure 3.20: Repeat assay on nanoplasmonic arrays of the assay in Figure 3.19. a) 
AFM’s were taken after MDA modification, and after b) secondary antibody incubation. 
c) Shows the corresponding spectra, after MDA (black); after antibody (red); and after 
antigen (blue) and after secondary antibody (pink). A clear red shift between each step 
can be seen. 
c) 
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3.3.4 Label free detection of C1q Protein as Pancreatic Cancer Biomarker        
using Nanoplasmonic Arrays 
After the characterisation, clone selection and optimisation of scFv anti-C1q antibody 
on the SPR platform, the assay was moved onto the nanoplasmonic array platform and 
its suitability as a label free format investigated. The assays performed include pure C1q 
protein in buffer, as initial detection; C1q protein in native serum, as a detection method 
in a complex protein mixture; and control assays using a non-target protein (C3 
protein), to investigate the specificity of scFv anti-C1q to its target analyte. 
The gold surface was initially functionalised with MDA, to make it suitable for 
antibody attachment. A transmission spectrum was then acquired prior to bio-
attachment. The spectra show the gold peak at 625 nm, which was the area observed for 
surface binding of the biomolecules. This peak is due to the interaction between the 
Surface Plasmon Polaritons and Raleigh Anomaly interaction at the gold/buffer 
interface, making it sensitive to refractive index changes on the surface. Raleigh 
anomalies are the conditions for which the corresponding diffracted orders are grazing 
to the surface. The coupling of localised surface plasmons leads to sharp extinction 
peaks on the low frequency side of the Raleigh anomalies [24-26]. The peak at 660 nm 
is due to the gold/glass substrate interaction, at which no shift would be expected due to 
the plasmon optical effect [27, 28]. Spectra in buffer were acquired at the different steps 
of the assay (before, after immobilisation of antibody and after incubating with the 
analyte; all after rinsing the sample with PBS buffer solution.  
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Nanoplasmonic Array C1q in Buffer Assay 
 
Figure 3.21 shows a typical label free assay for C1q in buffer using the nanoplasmonic 
arrays. The black curve shows the transmission spectrum after MDA functionalisation 
of the gold film at 627 nm. EDC/NHS coupling of the C1q scFv antibody results in a 
red-shift of the resonance dip of 4.6 nm (from 627 nm to 631.6 nm), shown by the red 
curve; indicating successful coupling of the antibody to the gold surface. Incubation 
with 4 µg/ml C1q protein as analyte (green curve) resulted in a further shift of 2.6 nm 
(from 631.6 to 634.2 nm) suggesting a binding event between the antibody and target 
Antigen. 
The total shift for the assay was approx. 7.2 nm. 
 
 
Figure 3.21: (a) Transmission spectra through a plasmonic sensor for the buffer 
experiment. The black line is the spectrum after MDA is attached, red is after C1q 
antibody immobilisation and green is after incubation of C1q antigen. (b) Zoomed in 
area showing the region of interest. 
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Step Wavelength (nm) Wavelength shift (nm) Molecule Size (nm) 
Au & MDA monolayer 627 0 1.3 
Antibody Layer 631.6 4.6  3  
Antigen Layer 634.2 2.6  45  
Table 3.3: Resulting shifts of the nanoplamonic assay shown in Figure 3.21. 
 
Specificity Assay 
For the specificity experiment, the coupled antibody was incubated with non-target 
protein, to observe if any shift would result from non-specific binding, and therefore 
either disprove or qualify the C1q detection assays. Figure 3.22 shows a typical 
specificity assay for C1q antibody using the nanoplasmonic arrays. The black line 
shows the transmission spectrum for MDA at 630 nm. The antibody coupling resulted 
in a 3.2 nm shift (red line), this was followed by incubation with 4 µg/ml non-target C3 
protein. As can be seen from the spectrum of Figure 3.22, no shift was observed after 
C3 incubation (blue line), indicating good selectivity of the scFv to its target protein. 
This was shown after incubating the gold film with 4 µg/ml target C1q protein (green 
line) which resulted in a shift of the spectrum by 3 nm, showing a binding event 
between the antibody and its analyte.  
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Figure 3.22:  (a) Transmission spectra through a nanohole array showing selective 
detection of C1q antigen. The black line is the spectrum before bio-attachment, red is 
after antibody binding, blue is after incubation of C3 antigen, and green is after 
incubation of C1q antigen. (b) Shows the spectra at the measured dip. 
 
Serum Assays 
Figure 3.23 shows a typical nanoplasmonic assay for the detection of C1q out of diluted 
human serum. This was to show that this method is suitable to detect target C1q protein 
out of a complex protein mixture. The assay was qualified by the selectivity test of 
Figure 3.22, and the control assay of Figure 3.24. The black line shows the initial 
transmission spectrum for the MDA functionalised sensor before antibody coupling (dip 
at 638 nm). The red line shows the antibody coupling, which resulted in a shift from 
636.7 nm to 639.2 nm (2.5 nm). 5% of Human Serum in PBS buffer (pH 7.2) resulted a 
further 2.5 nm shift in transmission spectra, to 641.7 nm. This assay shows that C1q can 
indeed be detected out of a complex protein solution using the C1q scFv antibodies on 
the nanoplasmonic arrays. 
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Figure 3.23: (a) Transmission spectra through a nanohole array showing detection of 
C1q in 5% serum. The black line shows Gold with MDA SAM layer; the red line shows 
the shift after coupling with C1q Antibody, followed by the green line after incubating 
with 5% human serum. (b) Zoomed in at region of interest. 
Control Assay 
The procedure in Figure 3.24 shows a typical control assay to determine the occurrence 
of non-specific adsorption for the nanoplasmonic array assays. Here, the diluted human 
serum assay is performed, but without the antibody coupling step. There should be no 
binding event occurring, and therefore no shift in transmission spectra, as the antibody 
is omitted from the procedure. All other steps (EDC/NHS, blocking and analyte) are 
kept as per usual procedure. The black line shows the transmission spectrum of the 
MDA functionalised gold at 636 nm. There was no red shift observed after incubating 
with the dilute serum solution (green line), showing that the shift following the serum 
incubation after antibody coupling in the assay performed in Figure 3.23 was indeed 
due to antibody/antigen interaction, and not due to non-specific adsorption of the serum 
proteins, which is a good validation of the C1q antibody assay on the nanoplasmonic 
arrays.  
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Figure 3.24: Control Assay to validate the C1q Assay; here, the assay from Figure 3.23 
was repeated, without the Antibody coupling step. The black line is MDA SAM layer, 
followed by incubation with 5% human serum. No shift was observed. 
 
Concentration Assays 
Calibration curves were attempted on this platform, however, it soon became clear that 
the nanoplasmonic arrays were too fragile for the regeneration step. The films flaked off 
when exposed to the HCL or Glycine solution. A few samples were successful in 
showing the increase of spectral shift with an increase of concentration, however. Figure 
3.25 shows a typical assay for a nanoplasmonic array with increasing concentration. 
1,2,4,8 and 10 µg/ml were assayed in increments, and the resulting shifts observed. As 
can be seen from the graph, an increase in concentration shows a further red shift in the 
spectrum, showing that the amount of shift is concentration dependendant, and could 
provide semi-quantitative data. Further analysis is required, however, as there was not 
enough data obtained due to the lack of successful samples assayed. 
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Figure 3.25: Graph for C1q increase of concentration on nanoplasmonic arrays. 
Concentrations were 0, 1, 2, 6, 8 and 10 µg/ml. 
 
3.3.4 Detection of C1q Pancreatic Cancer Biomarker using Optical Hybrid Set-Up 
The interrogation method of the nanoplasmonic arrays is based on optical transmission 
through the sensors, and monitoring of the shift in the spectral position of the resonance 
dip as the different biomaterials bind to the surface. Since the materials used for 
fabrication of the microfluidics components are transparent in the visible and near 
infrared, they can be easily integrated within an optical transmission setup. During the 
assay procedure, the spectral shifts are measured by recording transmission spectra and 
track the resonance wavelength, where the transmission spectra through the sensors 
were recorded and analysed. The LabVIEW design of the integrated system can be seen 
in Figure 3.26 and Figure 3.27. The main components of the Hybrid system consists of 
the microfluidics system, the optical system, a LabVIEW program to record and analyse 
the data. Briefly, the sensors are placed in the microfluidic holder and excited from the 
back by a collimated broadband light source. The light transmitted through the sensors 
was collected and collimated by an objective and then focused onto a ca. 50 µm slit. 
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The image through the slit was collimated by a lens, impinged onto a 1200 gr/mm 
grating and the dispersed light, i.e. the transmission spectrum, was focused onto a 
CMOS camera. The spectra were recorded in real time, and the shift of the resonance 
feature monitored by a LabVIEW program. 
This design could potentially be miniaturised for a handheld reader in Point-of care 
application. 
Further discussion of the optical hybrid set up can be seen in chapter 4. 
 
Figure 3.26: (a) custom optics set up and (b) microfluidics set up 
b) 
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Figure 3.27:  Sample addressing of the microfluidics set up. The sample holder was 
modified to hold the gold film nanoarrays used in the static assays. The microfluidics 
channel has four sensor spots, which can be addressed individual or together. 
Using the nanoplasmonic arrays, detection of C1q antigen in buffer and serum was 
undertaken using the integrated system. The assay procedure that was carried out for 
Figure 3.28 (a) and (b) are the same as the nanoplasmonic array static experiments: 
Prior to the experiment, MDA was deposited on the sensors for SAM assembly to 
facilitate EDC/NHS coupling of the antibody. After docking the nanoplasmonic array 
sample into the sample holder, EDC/NHS solution was injected over the sensor. The 
EDC activation of the surface was followed by a C1q antibody injection. The surface 
was then blocked with Ethanolamine- HCL and analyte was subsequently injected over 
the sensor.  
The EDC/NHS step can be clearly seen at in Figure 3.28 (a) at t = 400 sec. Also, the 
value of the slope at t = 800 s is slightly more negative after the antibody injection than 
before it, indicating successful coupling. The ethanolamine blocking step can be seen at 
t = 1,200. Finally, a clear decrease in the value of the slope can be seen at t = 1,700, 
upon injection of the serum for Figure 3.28 (a). This means the C1q Ab was able to bind 
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to the C1q Ag present in the serum. Commercially available human serum was used for 
this experiment, and therefore the detected concentration in C1q was unknown. To 
verify that non-specific binding was not occurring, a similar assay was carried out 
without the antibody present (buffer was injected over the sensor during this step, 
omitting the antibody), shown in Figure 3.28 (b). At t = 200 sec, the EDC/NHS 
refractive index response can be observed. At t = 600 sec, sodium acetate buffer pH 4.5 
was injected over the sensor, without C1q antibody present in the solution. At t = 900 
sec, the sharp response in RIU due to the high refractive index of Ethanolamine- HCl is 
visible during the blocking step. At t = 1,200 sec, 2% serum is injected over the sensor. 
No change in the signal indicates no non-specific binding occurs, and that the signal 
changes of the previous assays were indeed due to binding events between anti-C1q 
antibody and C1q protein. A validation assay was performed on the SPR-2 platform, 
using the same concentration and injection volumes as used for the hybrid system show 
the same characteristic curves for each stage of the injection. As the right slope was 
monitored during sample injection for the optical hybrid set-up, the sensogram is in 
inverse to the SPR-2 sensogram. 
 
Figure 3.28: (a) C1q 2 % Serum Assay in Hybrid System. The figure shows the signal 
response for the right slope during the assay Assay. (b): same assay with sodium 
acetate buffer only (coupling buffer, but no antibody) of the sensor showing no non-
Chapter 3: Bioassays on Nanoplasmonic Arrays 
128 
 
specific binding. The higher the refractive index of the solution, the greater the dip on 
the y-axis, giving an upside down sensogram when compared to the SPR-2. Note: in this 
figure, the right slope of the transmission dip was monitored. 
 
3.3.5 Label- Free Detection of BVD Antibody on Nanoplasmonic Arrays 
In this section, a virus assay is performed, to detect antibodies against the disease 
causing agent, as discussed in chapters 1 and 2. The disease causing virus is coupled to 
the surface to detect antibodies that indicate current or previous infection with the 
pathogen. Here, the nanoplasmonic arrays were utilised for the label free detection of 
BVD Virus, after developing a label free assay on the SPR-2 (chapter 2).The clean and 
SAM assembly is identical to the previous assays using the antibody molecules, as is the 
coupling procedure. BVD virus was EDC coupled onto the gold sensor surface, and 
incubated with anti-BVD antibody (Figure 3.29), 1% BVD positive bovine serum 
(Figure 3.30), and 1% BVD negative serum (Figure 3.31) and the suitability of the 
nanoplasmonic arrays as sensor for viral antibodies determined.  
 
Detection of BVD Antibodies in Buffer 
Assays for the detection of anti-BVD antibodies were first undertaken in buffer. Figure 
3.29 shows a typical assay performed on the nanoplasmonic arrays. The black line 
shows the transmission spectrum of the MDA functionalised sensor, with the dip at 635 
nm. 7µl/ml of BVD virus was then coupled to the surface, and resulted in a shift of 2.1 
nm of the transmission spectrum (blue line). This was followed by a shift of 0.8 nm 
after 10 µg/ml anti-BVD antibody incubation, shown by the red line. The total shift 
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after this assay was 2.7 nm, showing that anti-BVD antibody bound to the BVD coupled 
virus on the gold sensor surface. 
 
Figure 3.29: BVD Virus and Antibody assay. Black line is MDA; Blue line is after 
coupling with BVD Virus, and red line is after incubation with 10 µg/ml of anti BVDV 
antibody. The final shift after completion of the assay is 2.7 nm. 
 
Detection of Anti-BVD Antibodies in Serum 
Figure 3.30 shows a typical detection of antibodies against BVD in positive bovine 
serum (bovine serum sample 6266). The black line shows the transmission spectrum for 
the MDA functionalised sensor, with a dip at 633 nm. A shift of 1.9 nm was observed 
after coupling BVD virus (blue line). A further shift of 2.3 nm was observed after 
incubation with a 1% serum positive sample (in PBS), as shown by the red line. The 
total shift in transmission spectra for this assay was 4.1 nm. The greater shift in the 
serum assay, when compared to the antibody assay, was probably due to the low affinity 
of the antibody that was provided for the assay in Figure 3.29. Previous SPR assays 
showed that the polyclonal BVD antibody used showed a low affinity towards the virus. 
This could be due to the fact that either it wasn’t a high affinity antibody per se; or that 
it was the fact that whole virus, rather than fractions were used, which may not display 
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target antigenic binding sites. Incubating with 1% bovine serum with sample 6299 
showed a pronounced shift in the spectrum from virus to antibody in the serum assay 
performed subsequently, see Figure 3.31. A 4.1 nm shift shows that BVD antibody was 
detected in serum using this format, and that the nanoplasmonic arrays are a suitable 
label free method to ascertain BVD disease status in cattle.  
 
Figure 3.30: BVD Virus and Serum assay. Black line is MDA; Blue line is after 
coupling with BVD Virus, and red line is after incubation with 1% BVDV positive 
serum. The final shift after completion of the assay is 4.1 nm. 
 
Control Assay 
Figure 3.31 shows a typical assay performed as a control assay to validate the BVD 
serum assay from Figure 3.30. The black line shows the spectrum of the MDA 
functionalised gold sensor, with a dip at 633 nm. After BVD virus coupling, the 
transmission spectrum shows a shift of 1.6 nm (blue line). Following the incubation 
with a 1% dilution of BVD negative bovine serum (sample 452) in PBS buffer, a slight 
blue shift of 0.2 nm can be observed. This is possibly due to dissociation of some 
unbound virus on the sensor surface during the analyte incubation phase. This 
dissociation is usually masked by the red shift of the transmission spectra, when 
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incubating with the target antigen.  The total shift after this assay was 1.4 nm. The 
control assay undertaken confirms the results for the serum positive assay performed in 
Figure 3.30, as no red shift in transmission spectra can be observed using the serum 
negative sample, proving that the 1% serum positive assay was indeed true detection of 
BVD antibody in bovine serum, and not non- specific binding due to adsorption. The 
serum sample status of positive and negative were confirmed by ELISA (see chapter 2; 
section 2.3, table 2.1) 
 
 
Figure 3.31:  BVD control assay. Black line is MDA; Blue line is after coupling with 
BVD Virus, and red line is after incubation with 1% BVDV negative bovine serum. A 
slight blue shift is observed after Serum incubation, possibly due to some unbound 
Antibody being removed. No binding is observed. 
Assay 1st shift (Virus) 2nd shift (Ab) Total shift 
Serum Detection 1.9 2.3 4.2 
Antibody Detection 2.1 0.6 2.7 
Control 1.6 -0.2 1.4 
Table 3.4: Results of the assay shown in Figure 3.29-Figure 3.31. 
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3.4 Conclusion 
In the first part of this chapter, the fabrication and characterisation of the nanoplasmonic 
arrays were discussed. It was shown in the simulations and subsequent characterisation 
with different salt concentration, that the nanoarrays would be suitable as a biosensor 
platform. In practice, a vital step towards creating a working biosensor was developing 
a clean that would be suitable for purpose; effective at removing impurities from the 
surface, without damaging the thin gold surface. Previously, acid and plasma based 
cleans used in the group left the thin gold surface pitted, and often resulted in the gold 
film lifting from the glass substrate. The first task was therefore investigating a suitable 
cleaning procedure for use on the plasmonic nanoarrays. This was developed after a 
literary search, and a combination of mixed solvent clean, followed by 20 min of 
UV/ozone was established. This clean was the first clean trialled, and it turned out to be 
successful, and was therefore adopted in the group as a thin gold clean thereafter.  The 
next step was then to develop the surface functionalisation and determine the suitability 
of the surface for bio modification. The initial development of the bioassay steps was 
demonstrated using the well characterised Biotin/Streptavidin assay. This is a robust 
assay with a high affinity interaction, which is frequently used as a model system in 
biological characterisation. The characterisation was done using AFM imaging, to 
observe the change of roughness on the gold surface in the progressive assay steps and 
contact angle. A RAM anti IgG antibody static assay was subsequently performed on 
the nanoplasmonic arrays, and the assay steps characterised by AFM imaging and 
spectral analysis. After the clone optimisation procedure of anti-C1q scFv antibody on 
the SPR-2 platform, the assay was moved to the nanoplasmonic array platform. The 
nanoplasmonic arrays were shown to be a suitable label-free sensor for the detection of 
C1q in both buffer and serum, with the antibody showing high affinity and selectivity 
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towards its target antigen. After it was established that the plasmonic nanoarrays were 
suitable as biosensors using the static assays, the assays were subsequently transferred 
to an optical/microfluidics hybrid system. This system was developed towards a label 
free POC application method.  Here, a custom optical set-up was combined with a 
custom four channel SPR Microfluidics system. Initial assay development showed good 
promise for label-free detection using this platform. In chapter 2, label free detection 
using SPR-2 of the bovine disease BVD was discussed. In this chapter, the BVD assay 
was also moved to the nanoplasmonic arrays for detection on this platform. The 
platform proved itself as suitable biosensors, enabling detection of target molecules in 
pure buffer, as well as out of a complex solution. Control assays performed to determine 
any degree of non-specific binding showed that the shift in spectra of serum and 
antibody assays were indeed due to a binding event, as the controls performed resulted 
in no shifts of the spectra, as expected. We therefore conclude that the nanoplasmonic 
arrays are a robust, reliable platform, suitable for use as a label free biosensor. 
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4.1 Introduction 
In this chapter, we discuss Guided Mode Resonance Waveguides (GMR) as biosensors. 
The goal of the GMR sensors of this work is towards Point-of-Care (POC) diagnostic 
systems. Unlike the plasmonics, which used gold as a substrate, the GMR sensors are 
fabricated of SiNx. GMR fabrication is a relatively straightforward process, making it a 
low cost option as a potential biosensor. [1, 2] It’s also very easy to characterise, only 
requiring a surface normal transmission spectrum to measure the resonance when 
illuminated by a white light source. [3, 4] The wafer scale batch production of the GMR 
sensor is also been shown to be reproducible. [5, 6] To function as a sensor, the GMR 
waveguide requires sub-wavelength nanostructures on the silicon nitride (SixNy) 
surface, which is contained on a quartz / glass substrate. [7-9] 
Two assay modes were conducted with the GMR platform a) adsorption, where the 
GMR sensors were left bare and the biomolecules were dropped on directly and left to 
adsorb on the sensor surface. This was exclusively a static assay, measured in the 
Picoquant and b) surface modified; the GMR sensor surface was silanised to enable 
EDC/NHS coupling of an antibody. This mode was performed for both static and real 
time, microfluidics based assays. The real time assays were performed in the hybrid 
custom system, like the nanoplasmonic arrays (see chapter 3, section 3.4). In this 
section, the fabrication, simulation and assay development are discussed, as well as a 
move towards an optics/microfluidics hybrid system towards a POC system. 
4.2 Materials and Reagents 
The materials and reagents used in this section were Acetone, Trichloroethylene,  IPA, 
100 mM Dulbecco’s PBS (Phosphate buffered saline) pH 7.2, HCL, C1q Protein and C3 
Protein, N-NPPOC 3-Aminopropyltriethoxysilane, Toluene were all purchased from 
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Sigma Aldrich. Sodium Acetate Buffers, Amine coupling kit (1-ethyl-3-(3-
dimethylaminopropyl) carbodimide hydrochloride (EDC), ethanolamine-HCl pH 8.5; 
N-hydroxysuccinimide (NHS)) were all purchased from Sierra Sensor GmbH.; scFv 
C1q and C3 Antibody and Proteins were provided by Lund University. Alexa 647-
fluorophore tagged murine IgG and Rabbit anti-murine IgG antibody were purchased 
from Sigma Aldrich. Deionized water (18.2 MΩ cm) was obtained using an ELGA Pure 
Lab Ultra system. All SixNy substrates were fabricated in-house. BVD virus and 
monoclonal antibodies BVD specific to the envelop glycoprotein (Erns) of the virus 
were purchased from Animal and Plant Health Agency (APHA Scientific, UK). All 
reagents were used as received.  Positive and negative bovine serum samples were 
provided by Teagasc biobank (Moorepark, Ireland). 
 
4.3 Experimental 
GMR Fabrication 
The GMR sensor has an area of 200 μm × 200 μm, with a grating structure of a period 
of 435nm, filling fraction of 60% and etching depth of 200 nm.  
The wafer scale fabrication of the GMR can be done either by electron beam 
lithography or by nano-imprint. [10, 11] Electron beam lithography is costly but 
suitable for its flexibility required for the design optimisation, whereas nano-imprint is 
very suitable for low cost batch production. [11-13] In this work, the wafer scale 
fabrication process of the sub-wavelength nano-structures was developed using Electron 
beam Lithography. All development, fabrication and simulation of the GMR substrate 
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in this chapter were done by Mr. Md Nazmul Hossain of the Photonics group in 
Tyndall, as part of his PhD work. 
In brief, the process starts with a four inch glass wafer, on which SiNx is deposited. This 
is followed by the deposition of a thin layer of Chromium. 
The GMR sensor is a 1D Photonic Crystal grating with a precise and specific filling 
fraction and etching depth.  The Photonic Crystal pattern was written by electron beam 
lithography on ebeam resist (ZEP520) and then the pattern was transferred into the 
Chromium layer by using inductively coupled plasma (ICP) Cr dry etching. The ebeam 
resist was then stripped off and the pattern in the Cr layer was transferred into SixNy 
layer by using ICP dry etching again. Finally, the Cr was removed by wet etching (MS 
8 Cr etchant) to produce the desired PhC sensor, see Figure 4.1. The GMR substrate can 
be seen in Figure 4.2, with a zoom in of the grating structure that provides the sensing 
region of the substrate. 
 
Figure 4.1: Schematic of the fabrication process for the Photonic Crystal nano 
structures in SixNy on an insulating substrate a) spin coating of ZEP (ebeam resist) on 
the wafer with SiN and Cr deposited on it, b) pattern writing, c) Cr dry etching, d) 
stripping off the ZEP resist, e) transferring the pattern into the SiN layer by dry etching 
using Cr as a hard mask, f) striping off the Cr. 
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Figure 4.2: GMR sensor and zoom in of photonic crystal nanostructures on a sensing 
region. 
GMR Surface Functionalisation 
The GMR sensors were functionalised using N-NPPOC 3-Aminopropyltriethoxysilane 
(NPPOC-silane). The NPPOC-silane synthesis was developed by the University of 
Manchester and performed as follows: The SixNy substrates were cleaned using a mixed 
solvent clean and then dried with N2. The substrates were then cleaned further using O2-
plasma (2 min; 60 W). The cleaned substrates were subsequently transferred into a N2 
flow-box for deposition of SAM modification.  N-NPPOC 3-
Aminopropyltriethoxysilane (1 mM) in dry toluene was left for SAM formation for a 48 
hour deposition time. After SAM assembly, the substrates were rinsed with toluene and 
ethanol and then dried with N2. The silane layer can be further photo-deprotected by 
near-UV radiation (> 320 nm), thus making it very useful in the formation of patterned 
surfaces. The modified samples are now ready for use. 
Substrates before and after SAM depositions were characterized by water contact angle 
measurement, true non-contact mode atomic force microscopy and X-ray photoelectron 
spectroscopy. The water contact angle of clean bare substrates appeared to be < 2°. The 
contact angles increased to 65° for SixNy after formation of monolayer on the substrates. 
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Figure 4.3: Formation of SAM of NPPOC-silane on SixNy substrates. 
 
GMR Assay Procedure 
The assay conditions developed for the nanoplasmonic array assays in Chapter 3 were 
subsequently applied for the GMR assays in this Chapter. However, after the initial 
transfer of the gold assay from the (gold) nanoplasmonic arrays to the GMR platform, it 
became clear that the incubation time for the GMR needed to be extended. There 
appeared no binding events (i.e no shifts in the spectrum) after a one and a half hour 
incubation time. The incubation time was therefore increased to a minimum of two 
hours.  
 
Adsorption Assay 
For the adsorption assays, 100 µl of a 7 µg/ml of C1q antibody solution or ii) 7 µl/ml of 
BVD Virus solution were directly dropped onto the sensor surface for two hours. The 
surface was blocked with Ethanolamine-HCL for 20 minutes. This was followed by 
antigen incubation of i) 0.2% human serum for the C1q assay or ii) 10µg/ml of BVD 
antibody in buffer for the BVD assays iii) 1% bovine Serum for the BVD serum assays 
(either serum negative or positive) for a further two hours.  
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GMR modified Sensor 
For the modified sensor, the surface was activated using 100 µl EDC/NHS solution for 
30 min. 100 µl volume of 7 µg/ml antibody solution was dropped onto the sensor and 
left for two hours. The surface was blocked with Ethanolamine for 20 min before 
incubating it with i) 0.5µg/ml C1q antigen or ii) 0.2% human serum for a further 
minimum of two hours. For the selectivity assay, the sensor was incubated with C3 scFv 
antibody for two hours, after the 30 min EDC/NHS activation step. This was followed 
by blocking with Ethanolamine-HCL for 20 min. The sensor was then incubated with 
0.5 µg/ml of C1q in buffer for two hours, before rinsing the sample with 0.1 M of HCL. 
The sensor was then incubated with 0.5 µg/ml of target C3 protein in buffer for two 
hours. All volumes were 100 µl.   
 
Assay Procedure for the Optical/Microfluidics Hybrid System 
The static assays used in the microscope system were subsequently transferred to the 
custom built setup, using the silane functionalised GMR substrates. The sample was 
docked onto the sample holder in the custom system. For the C3 and C1q assay, the 
surface was activated with 80 µl of EDC/NHS. 80 µl of 20 µg/ml C3 scFv antibody was 
injected over sensor 2. 80 µl of 20 µg/ml C1q scFv antibody was injected over sensor 3. 
25 µl of Ethanolamine-HCL was injected over both sensors. This was followed by 80 µl 
of 2% human serum in PBS over both sensors. The flow rate for this assay was 25 
µl/min, with 0.1 M PBS as running buffer. For the C1q assay, the functionalised GMR 
surfaces were activated by a 60 µl injection of EDC/NHS, which was followed by a 60 
µl of C1q scFv antibodies (20 µg/ml) and blocked with Ethanolamine-HCl. A 
subsequent 60 µl Injection of 60 µl of 2 µg/ml of C1q protein in PBS was then 
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performed. The flow rate was kept at 20 µl/min throughout all assays, with 0.1M PBS 
used as running buffer. 
 
Fluorescence Assay  
For the fluorescent assay in the optical hybrid system, Silicon substrates were 
functionalised with the silanisation procedure discussed above. The surface was 
activated with EDC/NHS for 30 minutes. 20 µg/ml of Rabbit anti-murine IgG antibody 
was subsequently left to couple to the sensor surface for 2 hours and the surface blocked 
with Ethanolamine-HCL for 20 min. The substrate was then docked into the 
optical/microfluidics hybrid system sample holder. An injection of 50 µl of 10 µg/ml of 
murine IgG tagged with an ALEXA 647 fluorescent label was injected over the GMR 
sample surface. The flow rate for the murine IgG injection was 25 µl/min. The running 
buffer was 0.1 M of PBS. 
4.3.2 Simulations 
COMSOL Simulations were carried out to find optimised parameters for the working 
wavelength of 633 nm. The wavelength of 633 nm was selected because common optics 
(sources, detectors) are more sensitive and readily available at this wavelength. Figure 
4.4 shows the transmission spectrum (in buffer) obtained with the optimised parameters 
for the visible GMR. As can be seen, two resonance peaks are obtained, one at 633 nm 
and a second one at 763 nm. Figure 4.4 also shows the electric field profile at the two 
resonance wavelengths. It shows that the electric fields are concentrated at the surface 
of the sensor, explaining the surface sensitivity of the sensors. However, it can be seen 
that the electric field at 633 nm penetrates deeper into the superstrate while the electric 
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field at 763 nm stays confined to the interface. From these E-field distributions, it can 
be deduced that the 633 nm resonance would act as a bulk sensor (i.e. capable of 
monitoring change of refractive index “away” from the surface) whereas the second 
resonance at 763 nm would act as a true surface sensor. 
 
Figure 4.4: Simulation of the electric field at the resonance wavelengths (left: 633 nm, 
and right: 760 nm) of the GMR sensors 
The GMR consists of periodic arrangement of SixNy groove in a SixNy waveguide layer. 
The transmission spectrum (at normal incidence) through these structures exhibits dips 
or notches at specific spectral positions. These spectral positions of the notches are very 
sensitive to the refractive index at the surface, and therefore the sensors can be used for 
label-free sensing. The different steps of a label-free assay on those sensors can be seen 
in Figure 4.5. The blue line shows the transmission spectrum for buffer only. The green 
line shows the expected transmission spectrum after coupling of an antibody. The red 
line shows the expected transmission spectrum after addition of the target antigen. The 
simulations revealed that an attachment of 20 nm of bio-molecule (thickness expected 
from the biomolecules used in the PHAST-ID project; refractive index estimated to be 
1.45) on the GMR surface induces a redshift of the first resonance wavelength by 2.1 
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nm, see Figure 4.5. This structure shows a sensitivity of 0.084 nm per nm of bio-
molecule attachment. 
 
Figure 4.5: Simulation spectra through the GMR sensors showing the redshift of the 
spectral dip at the different stages of the assay. 
 
4.4 Results and Discussion 
Surface Characterisation 
In order to demonstrate the surface sensitivity of the sensor, a 30 nm layer of SiO2 with 
a refractive index of 1.45 was conformably deposited by PECVD on top of a fabricated 
GMR sensor. As can be seen, the layer deposition induced a redshift of 1.4 nm. This 
redshift confirmed the GMR sensors were able to detect slight change in refractive 
occurring at their surface, see Figure 4.6. 
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Figure 4.6: Shift of resonance wavelengths of GMR sensors prior to and after 
conformal coating of a 30nm layer of oxide in water. The shift measured after coating 
the surface was 1.4 nm 
4.4.1 GMR C1q Adsorption and modified surface Assay 
Initial bioassay procedures showed no binding, or very little binding. The initial 
characterisation was performed on plain SiN substrates, at University of Lund, using 
their microarray system, and in University of Manchester, to develop and characterise 
the silane functionalised surface, and as part of this work, to characterise the surface for 
the custom hybrid system using the functionalised plain SiN substrate. There weren’t 
any discernable problems using the plain modified substrate, however, once the 
substrates were processed to include the grating features, antibody coupling and 
adsorption became unsuccessful. The first step was to increase incubation time, which 
worked in some cases, but resulted in only minimal shift at most. Finally, the increase in 
hydrophobicity using the GMR silanisation process, as well as the small size of the 
grating structure resulted in attempting the assays at a lower concentration than the 20 
µg/ml of antibody used. The thought was that the increase in hydrophobicity, as well as 
the small structure of the sensor surface resulted in a “bubble” of aggregated 
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biomaterial, unable to make contact with the sensor region of interest. The concentration 
was dropped to 7 µg/ml of antibody for both adsorption and functionalised sensor. As 
can be seen from the C1q adsorption assay in Figure 4.7, the drop in concentration 
appears to have solved the problem, and a working assay was obtained. 
 
C1q Adsorption Assay 
Figure 4.7 shows a typical adsorption assay for C1q scFv antibody for the detection of 
C1q in 0.2% Serum. The blue line shows the transmission spectrum for PBS buffer 
only, with the dip at 688nm. The red line shows the transmission spectrum after 
incubating with C1q scFv antibody, resulting in a spectral shift of 1.6 nm. The green 
line shows the transmission spectrum after incubation with 0.2% human serum. A 
further shift of 0.9 nm can be observed, indicating that C1q was indeed detected in 
human serum using this format. The total shift of the transmission spectrum for this 
assay was 2.5 nm. 
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Figure 4.7: C1q adsorption assay on GMR sensor. Blue line is before assay; red is after 
7µg/ml C1q antibody in sodium acetate pH 4.5 incubation; green is after incubation 
with 0.2 % serum in PBS. A clear shift can be observed after each assay step. 
 
Surface Modified Assays 
Figure 4.8 shows a typical assay for a surface functionalised GMR sensor for the 
detection of C1q in buffer. The blue line shows the transmission spectrum for PBS on 
the modified surface. The dip lies at 751.5 nm. The red line shows the transmission 
spectrum after coupling C1q scFv antibody, which results in a spectral shift to 753 nm. 
The green line shows the transmission spectrum after incubation with C1q protein in 
buffer. A slight spectral shift of 0.2 nm can be observed.  
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Figure 4.8: Surface modified GMR assay using C1q antibody and 0.5 µg/ml of C1q 
protein in PBS buffer. 
 
Selectivity Assay 
Figure 4.9 shows a typical selectivity assay for C3 scFv antibody. The blue line shows 
the transmission spectrum for buffer only on the functionalised GMR sensor. The 
yellow line shows a shift to 692.5 nm after coupling the C3 scFv antibody. The sample 
was then incubated with non-target C1q protein in PBS buffer (red line). No shift in the 
spectrum was observed. The sample was carefully rinsed with a 0.1M HCL solution, to 
ensure no remnants of C1qprotein remained on the sensor surface. The GMR sensor 
surface was subsequently incubated with target C3 protein, which resulted in a shift of 
0.2 nm. Although only resulting in a small shift between antibody and target antigen, 
this assay still showed good selectivity in target protein detection for this sensor 
platform. 
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Figure 4.9: C1q antibody assay on GMR with modified surfaced. Blue line is antibody, 
yellow line is after incubation with C3 antibody; red line is after addition of (non-
complementary) C1q protein. Green is after incubation with C3 antigen. 
 
Functionalised GMR C1q Serum Assay 
Figure 4.10 shows a typical assay for the detection of C1q in human serum. The buffer 
spectrum was omitted, for visibility of the antibody/antigen spectral shift. The red line 
shows the transmission spectrum after antibody coupling. The spectrum shifted 0.9 nm 
after incubating with 0.5% human serum (green line). The assay shows that C1q protein 
is detected in human serum, using this format. 
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Figure 4.10: Transmission spectra through a functionalised GMR sample showing 
detection of C1q in dilute serum. A shift of 0.9 nm was observed. 
 
4.4.2 GMR Adsorption Assays for the Detection of BVD Antibodies 
Serum Assay 
The BVD virus assays of chapter 2 and 3 were also subsequently moved onto the GMR 
platform. Serum positive, serum negative and pure antibody in buffer assays were 
performed to determine if the GMR sensors would be a suitable platform for diagnostic 
detection of infectious diseases. Disease status of the bovine serum samples were 
confirmed with ELISA, see chapter 2. Figure 4.11 shows a typical adsorption assay for 
the detection of BVD antibodies in serum positive bovine serum. The blue line shows 
the transmission spectrum of PBS buffer on the unmodified sensor surface at 730.9 nm. 
A shift of 0.2 nm in the transmission spectrum can be observed after incubating with 
BVD virus (red line). A further 0.8 nm shift in the transmission spectrum can be seen 
after incubation with 1% BVD antibody positive bovine serum. This indicates that BVD 
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antibodies were detected in bovine serum using the GMR sensors as method for 
detection. 
 
 
Figure 4.11: BVDV Serum positive assay. BVD virus is incubated with 1% bovine 
serum to detect BVD antibodies present. 
 
Control Assay 
Figure 4.12 shows a typical control assay to qualify the positive serum result, to 
determine if the positive signal for the assay performed in Figure 4.11 was due to non-
specific adsorption of serum proteins, or if it was indeed a binding event between 
antibody/antigen. The control assay was performed with a serum negative bovine serum 
(sample 452). The blue line shows the transmission spectrum for PBS on the GMR 
surface. BVD virus was incubated on the sensor surface, resulting in a 0.2 nm shift of 
the transmission spectrum (red line). A virus negative serum sample was then incubated 
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on the virus-adsorbed GMR surface, which resulted in a slight blue shift of -0.2, 
possibly due to some of the virus being desorbed of the surface during incubation with 
the negative serum. No binding occurred during this assay, indicating that the shift 
observed after serum positive incubation of Figure 4.11 was indeed due to the binding 
of anti-BVD antibodies contained in the serum to the BVD virus adsorbed to the sensor 
surface. 
 
Figure 4.12: Control assay. BVD negative sample is incubated with BVD virus 
adsorbed to the sensor surface. 
 
Antibody in Buffer Assay 
Figure 4.13 shows a typical assay for the detection of anti-BVD antibodies using 
surface sensor adsorbed BVD virus. The blue line shows the transmission spectrum for 
PBS on the unmodified sensor surface. After incubation with BVD virus, the 
transmission spectrum is seen to shift 0.2 nm. A further shift of 0.2 nm can be seen after 
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incubation with anti-BVD antibody (green line). This shows that the GMR sensor is 
able to detect anti-BVD antibody in PBS buffer. 
 
Figure 4.13: BVD assay for the detection of anti-BVD antibody in PBS buffer. Blue line 
is substrate only; red line is after adsorption with BVD Virus; green line is after 
incubation with 10 µg/ml anti- BVDV antibody in PBS. 
 
Assay 1st Shift (in nm) 
(capture) 
2nd Shift (in nm) 
(analyte) 
Total Shift (in nm) 
Serum 0.2 0.8 1 
Antibody 0.2 0.2 0.4 
           Serum Control 0 -0.2 -0.2 
Table 4.1: BVD GMR Assay Table Results of the BVD assays; Figure 4.11-Figure 4.13. 
GMR background noise level was found to be low, with a spectral resolution of 0.1 nm. 
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4.4.3 GMR assays on optics/microfluidics hybrid system 
Subsequently to the static assays, like the nanoplasmonic arrays, the GMR assays were 
also transferred to the optical hybrid system, see Figure 4.14. The parameters and 
system specifications are discussed in Chapter 3, section 3.3.4. Refer to that chapter and 
section for explanation of the system set up.  
 
Figure 4.14: Custom build optics set up and microfluidics sample holder. 
 
Fluorescent Characterisation Assay 
As mentioned in the introduction of this chapter, the GMR assays were performed both 
as adsorption (static) assay, and as a surface functionalised sensor, suited for EDC 
coupling. The surface of the bare SixNy GMR lends itself reasonably to the static 
adsorption assays, as can be seen in section 4.4 of this chapter. For the transfer of the 
assay to the custom hybrid microfluidics system, however, surface functionalisation to 
enable coupling of the antibody was required. That is because unlike the static 
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experiments, which have hours of incubation time, the dynamic assays in the 
microfluidics system only have minutes of contact time with the surface, requiring the 
antibody to be immobilised in a short matter of time. As the biomolecules flow over the 
surface of the sensor, they need to be immobilised and bound to the sensor surface, to 
enable the subsequent assay procedure. To enable covalent coupling of the antibody to 
the GMR chemistry using EDC/NHS chemistry, carboxyl groups needed to be 
generated at the surface of the SixNy sensors to allow attachment of the antibodies via 
EDC/NHS chemistry. The surface functionalisation chemistry was developed by 
University of Manchester as part of the PHAST-ID project. They synthesised and 
deposited a linker molecule that exhibited carboxyl groups upon UV exposure, allowing 
for surface activation via EDC/NHS. As discussed in section 4.3 of this chapter, N-
NPPOC 3-Aminopropyltriethoxysilane (NPPOC-silane) was chosen for the surface 
modification of the GMR sensor surface. The surface functionalisation chemistry was 
initially developed on planar SiO2 and SixNy substrates and then transferred onto the 
GMR sensor. Figure 4.15 shows a typical characterisation assay of the surface 
functionalised planar SiN substrate, using a rabbit anti-murine anti-IgG antibody that 
was coupled to the surface to detect an ALEXA 356 fluorophore-tagged murine IgG 
that was injected over the substrate surface using the optical hybrid system, as antigen.  
The ALEXA 356 emits in the orange colour wavelength range. At t =200 sec, the 
antibody coupled substrate can be seen in the sample holder. The four sensor spots are 
visible, no fluorescence signal is present. At t = 280 sec, ALEXA 356 tagged murine 
IgG is injected over the sensor surface over sensor 1. Fluorescence is visible at the 
injection and evacuation ports, as well as over sensor 1. At t = 400 sec, A fluorescent 
signal can be clearly observed over sensor 1, indicating that the antibody coupling was 
successful and a working bioassay was obtained using this format.  
Chapter 4: Point-of-Care Label-free Diagnostics using GMR Waveguides 
159 
 
 
Figure 4.15: Fluorescence microfluidics assay to characterise the functionalised silicon 
substrate that were eventually used for the GMR sensor, performed in the SPR-4 custom 
microfluidics system. The diagram above each image shows what happens during the 
assay. 
Figure 4.16 is a typical sensogram that shows the SPR signal for the fluorescence assay.  
At t = 280 sec, a sharp increase in RIU can be observed during the injection of the 
ALEXA-tagged antigen. A sharp decrease of the refractive index can be observed at the 
end of the injection at t = 290. This is due to the removal of excess antigen from the 
surface of the substrate. The fluorescent signal can be seen to decay steadily over time, 
which is due to the decay in fluorescence of the fluorophore. 
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Figure 4.16: SPR signal for the fluorescence assay shown in Figure 4.15. The decay in 
signal is due to the decay in fluorescence of the ALEXA 356 fluorescent tag. 
 
GMR assay of scFv Antibodies on Optical/Microfluidics hybrid system 
After determining the suitability of the surface functionalised GMR sensors for use in 
the microfluidics system, the assay procedure was moved to the custom built hybrid 
system. Figure 4.17 shows a typical assay for the scFv antibodies for the detection of C3 
and C1q protein as a biomarker for pancreatic cancer. The Figure shows the sensogram 
obtained for the right slope. Figure 4.17 a) shows C3 scFv antibody assay on sensor 2, 
Figure 4.17 b) shows C1q scFv antibody assay on sensor 3. At t = 300 sec, the change in 
RIU due to the EDC/NHS injection is visible in both figures. At about t = 700 sec, C3 
scFv antibody is injected over the sensor (4.16 a); at t = 800 sec, C1q scFv antibody is 
injected over sensor 3 (4.16 b). At t = 3000 sec, 2% human serum is injected over both 
sensors. A decrease in refractive index, clearly discernible in Figure 4.17 a), indicates 
that C3 protein from the human serum bound to the antibody coupled on the sensor 
surface, which was clearly detectable using this format. Figure 4.17 b) also shows a 
decrease, even if to a lesser degree than the C3 assay. The problem with the injection 
over this sensor spot was leakage, where problems were encountered where the 
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injection over the sensor wasn’t creating a single stream over the sensor, but leaked out 
over the surrounding area. This was addressed by amending the design of the sample 
holder.  The sharp, thin peaks within the assay (at t = 1,700 for a) and t = 2,500 secfor 
b), for example) are air bubbles in the system. 
 
Figure 4.17: GMR Serum assay on custom system (right slope). a) Shows a C3 assay on 
sensor 2, b) shows C1q assay on sensor 3. 
 
Due to the amount of air bubble inclusions during the assay procedures, the assay 
parameters were investigated to see if air bubbles could be avoided during the assays. It 
was found that dropping the injection volume from 80 µl (the max for the microfluidics 
hardware) to 60 µl, and decreasing the injection flow time to 20 µl/min was the “sweet 
spot” for the avoidance of air inclusions during sample solution injection. Figure 4.18 a) 
shows a typical assay for C1q with those parameters, with Figure 4.18 b) showing a 
comparable C1q assay on the SPR-2. As can be seen in Figure 4.18 a), at t = 500 sec, 
the refractive index increase due to the EDC/NHS injection can be observed. At t =900 
sec, two injections of C1q scFv antibody was made. At t = 1,800 sec, the Ethanolamine 
blocking step can be seen with its sharp increase in peak due to the high RIU. At t = 
 
a) b) 
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2,300 sec, two injections of C1q antigen in buffer were performed. An increase in RIU 
after the completed assay can be seen. No air bubbles can be seen after changing the 
parameters, however, it provided a new issue of decreased contact time of the sample 
solutions with the GMR sensor surface. The change of parameters provided no issues 
for the nanoplasmonic array gold surfaces discussed in chapter 3, section 3.3.4, for the 
GMR substrates, which required a longer contact time, as previously discussed, results 
weren’t as definite. As the issue was a hardware problem, increasing the maximum 
injection volume of the microfluidics design would most likely increase GMR assay 
performance using this format. 
 
Figure 4.18: GMR assay (left slope) of C1q antibody (14 µg/ml), detecting pure antigen 
I buffer (2 µg/ml), and corresponding SPR-2 assay at the same concentrations 
 
 
 
  
 
a) b) 
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4.5 Conclusion  
In this chapter, we discuss the fabrication, characterisation and assay development of 
SxNy GMR sensors as a method of label-free detection of disease markers. GMR 
sensors are potential sensor for POC application, due to their low-cost, high throughput 
manufacture. The initial assay development proved to be a challenging task. It became 
clear that the assays could not be moved directly from the nanoplasmonic arrays at their 
parameters. Initial assay procedures showed no binding, or very little binding. The 
initial characterisation performed on planar SiN substrates with silane functionalised 
surface showed no discernable problems, however, once the substrates were processed 
to include the grating features, antibody coupling and adsorption became unsuccessful 
or at best difficult. The first step taken was to increase incubation time, which worked in 
some cases, but resulted in only minimal shift at most. Finally, it was thought that the 
increase in hydrophobicity using the GMR silanisation process, as well as the small size 
of the grating structure resulted in a “bubble” of aggregated biomaterial, unable to make 
contact with the sensor region of interest. The concentrations were dropped for both 
adsorption and functionalised sensor. As can be seen from the C3 and C1q assays, and 
the BVD assays above, the drop in concentration appears to have solved the problem, 
and a working assay was obtained. The static assays were then moved to the custom set 
up, once the assays were deemed a success. The fluorescence surface characterisation 
assay performed previously, using the planar functionalised substrates, show that the 
GMR sensor is suitable substrate for this method. However it became clear that the 
problems involving the static assay also hindered a successful microfluidics assay. 
Whereas the contact time of the biomolecules on the gold surface of the nanoplasmonic 
arrays was sufficient, the modified GMR sensor surface required a longer contact time, 
as reflected by the static assays. The main problem turned out to be a hardware problem 
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concerning the microfluidics pumps. It was established that the volume was limited to 
80 µl (The SPR-2 has a top volume of 200 µl, compared to the 80 µl of the SPR-4 that 
was custom built for the hybrid set-up), but that at that injection volume, the inclusion 
of air bubbles became a problem. After some experimenting using different flow rates 
and injection volumes, it appeared that the flow rate could not be decreased to further 
than 20 µl/min, or it would result in air bubbles, meaning contact time could not be 
sufficiently increased that way. Furthermore, there was a need to decrease the injection 
volume to 60 µl, anything above that would also result in air bubble formation. These 
handicaps resulted in weak assay performance for the GMR sensors in this set up. 
Unfortunately for this project, further development of the microfluidics hardware was 
outside the scope of this project. However, it is evident from this work that GMR 
sensors would lend themselves as suitable, low cost, label free biosensors that would 
enable rapid detection of disease markers for point-of-care diagnostics. 
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5.1 Summary and Conclusion 
This thesis explored the development of label free optical diagnostic assays on different 
platforms towards low cost point of care diagnostics in veterinary in medical 
application. We explore three different methods: Surface plasmon resonance, using a 
commercial SPR instrument; nanoplasmonics using in-house fabricated nanoplasmonic 
arrays; and guided mode resonance sensors, also fabricated in house, as a low cost 
option for point-of-care diagnostics for future medical application.  
Chapter 2 discusses the development of a label free, rapid simultaneous virus assay 
using surface plasmon resonance for the detection of antibodies in response to viral 
infection by BVD and IBR in bovine serum on the SPR-2 platform. The assays were 
developed due to the current need in veterinary diagnostics to quickly and accurately 
assess the health status of a cattle herd and prevent the potential spread of BVD and 
IBR, two of the most common bovine infectious diseases affecting cattle health in 
Ireland. Current methods are barely adequate, as they are time consuming and costly. 
This work aims to develop and alternative that may ultimately aid in the containment of 
those diseases and protect herd health. In this work we show the detection of antibodies 
specific to BVD and IBR virus, and the accurate identification of serum positive and 
serum negative disease status, which was confirmed by ELISA assays performed in-
house and by Teagasc. The SPR results were obtained in a matter of minutes, which is a 
far superior time frame when compared to the 24 hours required by the ELISA assays, 
and were run at the same time, whereas the ELISA assay requires two separate assays to 
be performed for IBR and BVD.   
In Chapter 3, we explore the fabrication and characterisation of nanoplasmonic arrays 
on a gold film as a potential label free biosensor towards point-of-care diagnostics. This 
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part of the thesis involved the project work for the development of a label-free point-of-
care diagnostic method to pancreatic cancer. Pancreatic cancer is a lethal, difficult to 
detect cancer with the highest mortality rate of any cancer per organ site. A project 
partner developed antibodies specific to a proposed panel of serum biomarkers for a 
pancreatic cancer serum signature. The role of this work was to screen a number of 
those antibodies and develop label-free assays on the nanoplasmonic platform; in 
particular, C1q. C1q scFv antibody clones as a biomarker to pancreatic cancer were 
screened on the SPR-2 platform, and then transferred to the nanoplasmonic array 
format. Nanoplasmonic arrays were used in both optical/microfluidic benchtop hybrid 
system and static assays, to detect C1q antigen in buffer and serum. The detection of 
BVD antibodies, using BVD virus, in buffer and serum are also performed using the 
nanoplasmonic array static assays. The optical/microfluidic hybrid system is an in-
house, custom build benchtop system that serves as a prototype for a potential future 
miniaturised label-free point-of-care format. Both static and dynamic assays showed 
selectivity, sensitivity and accurate determination of the presence of the target 
molecules. The dynamic assays provided results in a matter of minutes and show great 
promise for a potential POC biosensor.  
Chapter 4 describes the fabrication and characterisation of Guided Mode Resonance 
(GMR) sensors on a SiN substrate as a possible low cost option for a point of care 
diagnostic biosensor. Two different modes of biomolecule attachment are explored; 
adsorption and covalent coupling after functionalising the GMR surface by silanisation. 
Static C1q detection assays are performed to determine the suitability of the GMR as 
sensor for the detection of pancreatic cancer biomarkers; Static BVD virus assays are 
also performed to explore antibody detection against a bovine disease causing agent 
using this platform. Finally, the GMR is transferred to the benchtop hybrid system, to 
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carry out C1q detection on this platform and determine the suitability of this substrate 
for microfluidic assaying. This format leads on from the nanoplasmonic arrays as a 
potential point-of-care sensor with a more cost-effective manufacturing option. 
 
5.2 Future Work 
There is currently a great interest in optical POC technologies that include the 
applications of microfluidics, due to the potential for miniaturisation and integration of 
complex functions that facilitate their usage in limited resource settings and for direct 
on patient care. The rapid, label free result generation and the ability to develop 
multiplex formats offer attractive prospects for the future of diagnostics using this 
technology. The nanoplasmonic arrays and GMR sensors developed in this work offer 
potential low cost, robust biosensors with the capacity to generate accurate and reliable 
results rapidly for potential POC application. The optical hybrid set-up is a promising 
platform that can use nanoplasmonic or GMR substrates for diagnostic assaying. The 
next step is to miniaturise the platform and integrate the optics and microfluidics into a 
handheld device for POC application. 
Current work in the NTG group is being carried out in conjunction with Teagasc to 
develop a label free POC system for the detection of BVD in cattle. There is also 
interest in further developing the simultaneous BVD and IBR assay. Further work is 
required to address the NSA issue, and to perform statistical analysis on more samples 
to accurately establish the cut-off point for the serum negatives, to assure the correct 
differentiation of serum positive and serum negative. University of Lund is in the 
commercialisation phase for a POC device for the detection of pancreatic cancer, using 
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the panel of biomarkers and scFv antibodies optimised and the assay procedures 
developed as part of this work. 
There is great potential for a multiplex format biosensor that would enable the 
simultaneous detection of a number of chosen disease markers using the nanoplasmonic 
arrays and GMR sensors. Current work involves improving the fabrication and 
processing of the substrates, as the substrates have inherent variability due to the way 
they are fabricated at present. It is also  labour intensive and low throughput. The 
photonics group in Tyndall is currently developing a Nano imprint process which would 
enable uniformity in substrate manufacture, as well as reducing labour and increasing 
throughput.  
Finally, further development and miniaturisation of the custom hybrid platform would 
allow for a low cost, multiplexable POC system for accurate and rapid label free 
diagnostics of disease markers. This work is on-going in the NTG group.  
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A1. Abbreviations 
Ab  Antibody 
AFM  Atomic Force Microscopy 
Ag  Antigen 
Au  Gold 
BoHV-1  Bovine Herpesvirus-1 
BVDv           Bovine Diarrhoea Disease virus 
CCD  Charge-Coupled Detector 
Cr  Chrome 
DI  De-ionised 
DNA  Deoxyribonucleic Acid 
EDC  ethyl-(N’,N’-dimethylamino)propylcarbodiimide hydrochloride 
ELISA  Enzyme-Linked Immunosorbent Assay 
EOT  Extraordinary Transmission 
Fab’                Fragment antigen binding 
Fc                   Fragment crystallisable region 
FDTD  Finite Difference Time Domain 
FIB  Focussed Ion Beam 
GMR              Guided Mode Resonance 
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H chain           Heavy chain 
HCl  Hydrochloric Acid 
HI                   Hydrodynamic Isolation 
IBR                 Infectious Bovine Rhinotracheitis 
IgG  Immunoglobulin G 
IPA  Isopropanol Alcohol 
kDa                 Kilo Dalton 
L chain            Light chain 
LED  Light Emitting Diode 
LOD               Limit Of Detection 
LSP  Localized Surface Plasmon 
mAb               Monoclonal Antibody 
MDA  Mercaptododecanoic acid 
MHDA Mercaptohexadecanoic acid 
MW                Molecular Weight 
N2  Nitrogen 
NaCl  Sodium Chloride (Salt) 
NaOH             Sodium Hydroxide 
NHS  N-hydroxysulfosuccinimide 
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PBS  Phosphate Buffered Saline 
PDAC             Pancreatic Ductal Adenocarcinoma 
PDMS  Polydimethylsiloxane 
PhC                Photonic Crystal 
PI                   Persistently Infected  
PML               Perfectly Matched Layers 
POC  Point Of Care 
RA  Raleigh Anomaly 
RIU  Refractive Index Unit 
RMS  Root Mean Square 
RNA               Ribonucleic acid 
RT-PCR          Reverse Transcriptase Polymerase Chain Reaction 
SAM               Self-assembled Monolayer 
SEM  Scanning Electron Microscopy 
scFv  Single Chain Variable Fragment 
SiN  Silicon Nitride 
SNT                Serum Neutralisation Test 
SP                   Surface Plasmon 
SPP  Surface Plasmon Polariton 
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SPR  Surface Plasmon Resonance 
UV  Ultra Violet 
VCSEL Vertical-Cavity Surface-Emitting Laser 
VH                  Variable Heavy 
VL                  Variable Light 
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